Immune responses against tumors controlled by the actin cytoskeleton : lessons from primary immunodeficiencies by Kritikou, Joanna Sara
From Microbiology, Tumor and Cell Biology 
Karolinska Institutet, Stockholm, Sweden 
IMMUNE RESPONSES AGAINST TUMORS 
CONTROLLED BY THE ACTIN 
CYTOSKELETON 
 
LESSONS FROM PRIMARY 
IMMUNODEFICIENCIES 
Joanna S. Kritikou 
 
Stockholm 2017 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cover illustration: “NK cell forming an immune synapse with a tumor cell”  
by Sofia Kritikou 
All previously published papers were reproduced with permission from the publisher. 
Published by Karolinska Institutet. 
Printed by Eprint AB 2017 
© Joanna S. Kritikou, 2017 
ISBN 978-91-7676-840-2 
Immune Responses against Tumors Controlled  
by the Actin Cytoskeleton 
Lessons from Primary Immunodeficiencies  
 
THESIS FOR DOCTORAL DEGREE (Ph.D.) 
Publicly defended at Karolinska Institutet,  
Lecture Hall Cell and Molecular Biology (CMB), 
Berselius väg 21, Karolinska Institutet, Solna Campus, 
Friday November 3
rd
 2017, 09.00. 
By 
Joanna S. Kritikou 
Principal Supervisor: 
Associate Professor Lisa Westerberg 
Karolinska Institutet 
Department of Microbiology, Tumor,  
and Cell Biology 
  
Co-supervisor(s): 
Dr. Hanna Brauner 
Karolinska Institutet 
Department of Microbiology, Tumor,  
and Cell Biology 
 
Assistant Professor Robert Månsson 
Karolinska Institutet 
Department of Medicince, Huddinge 
Center for Hematology and  
Regenerative Medicine 
 
Associate Professor Marianne Farnebo 
Karolinska Institutet 
Department of Oncology-Pathology 
 
Opponent: 
Associate Professor Loïc Dupré 
Toulouse Purpan University Hospital  
Centre de Physiopathologie de Toulouse Purpan  
 
Examination Board: 
Associate Professor Bence Rethi 
Karolinska Institutet 
Department of Medicine, Solna 
  
Associate Professor Andreas Lundqvist 
Karolinska Institutet 
Department of Oncology-Pathology 
  
Professor Roger Karlsson 
Stockholms University 
Department of Molecular Biosciences 
 
 
 
  
To my parents, 
for giving me everything 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is nothing like looking, if you want to find something. 
You certainly usually find something, if you look,  
but it is not always quite the something you were after. 
 
J.R.R Tolkien 
  
  
  
ABSTRACT 
The actin cytoskeleton and its regulators are vital for cellular processes such as cell motility 
and immune synapse formation. In this study, the aim was to dissect the role of two of those 
regulators, WASp and MKL1, in immune cells and their role in tumorigenesis. Additionally, 
we pharmacologically target an enzyme involved in fatty acid metabolism in monocytes and 
assess the impact on the actin cytoskeleton. 
Deleterious mutations in WASp cause the Wiskott – Aldrich syndrome (WAS) and activating 
mutations cause X-linked neutropenia (XLN). Both immunodeficiencies are accompanied by 
a higher risk of developing malignancy. In paper I we investigated NK cell function when 
WASp is absent. We found that WASp-deficient NK cells were hyporesponsive to 
stimulation and failed to form immune synapses with tumor cells in vitro and to reject MHC 
Class I-deficient splenocytes in vivo. However, we observed no defect in lymphoma 
development or rejection in vivo. IL-2 is a cytokine known to stimulate NK cell cytotoxicity. 
When incubating NK cells with IL-2, we could rescue the functional defects of degranulation 
and cytokine secretion, as well as actin polarization to the synapse in vitro. Additionally, 
when injecting the IL-2 treated NK cells into WASp-deficient that have received MHC Class 
I-deficient splenocytes, we could also rescue the in vivo defect. Interestingly, we found that 
all the lymphomas we used in this study were capable of producing large amounts of IL-2 in 
vivo, which could be the reason that WASp-deficient NK cells were capable of handling the 
tumors similarly to wildtype. Therefore, we conclude that the malignancies observed in WAS 
are likely due to immune surveillance defects and can be circumvented by immunotherapy. In 
paper II, we dissect the role of activating WASp mutations in NK cell and T cell 
functionality in the context of tumor development. We found that NK cells and T cells from 
mice with activating mutations WASp
L272P
 and WASp
I296T
 were capable of responding to 
receptor stimulation as well as form immune synapses in vitro. WASp
L272P
 mice could reject 
lymphomas to the same extent as wildtype and had higher rejection rates of MHC Class I-
deficient splenocytes in vivo. Additionally, NK cells from WASp
L272P
 and WASp
I296T
 mice 
had lower amounts of KLRG1, an inhibitory receptor. NK cells from XLN patients with the 
L270P mutation were hyporesponsive to stimulation with tumor cells but not to 
PMA/Ionomycin and had decreased KLRG1 expression. Interestingly, the patients’ T cells 
had increased amounts of KLRG1, high Granzyme B content and could respond to 
PMA/Ionomycin stimulation. There was also the appearance of a CD4
+
CD8
low
 population of 
T cells in the patients. Therefore, the malignancies observed in XLN are more likely due to 
increased cell intrinsic transformational capacity than defects in immunosurveillance. While 
the cytoplasmic role of WASp is extensively studied, both in general and in the context of 
this thesis, the nuclear role of WASp is less known. In paper V, we sought to determine that 
role. We show that WASp is indeed present in the nucleus and mediates active transcription. 
Additionally, we observed that WASp drives transcriptional events associated with T cell 
development and does this through its regulation of T cell-specific transcription factor TCF1. 
We also found that WASp interacted with TCF1 but had no direct binding to it; the proteins 
could instead form a macromolecular complex. 
  
Paper III, focuses on the actin regulator MKL1 and attempts to dissect its role in the 
development of Hodgkin’s lymphoma (HL). We investigated triplets with a deletion in the 
first intron of MKL1, two of which developed and were treated for HL. We found that the 
deletion induced increased expression of MKL1. In EBV-transformed B cells we generated 
from the triplets, we saw that the cells from the unaffected triplet (termed HL0) showed 
decreased aggregation, increased spreading and protrusion formation on slides, increased 
proliferation, and increased genomic instability. These phenotypic traits have all been 
connected to a more invasive cellular state. These findings, along with the increased 
expression of MKL1 in various lymphomas that we looked at, provide evidence for the link 
between MKL1 and lymphoma development.  
The actin cytoskeleton can be hijacked by cancer cells to produce highly motile and invasive 
cells. In paper IV we used and inhibitor for the enzyme 15-lipoxygenase-1 (15-LOX-1) that 
mediates metabolism of fatty acids. We showed that the enzyme is necessary for the 
formation of podosomes in dendritic cells (DCs), which could contribute to invasion and 
metastasis. The DCs were also impaired in their migratory and endocytic capacity when 
treated with the inhibitor. T cell responses when using the inhibitor on DCs were only 
marginally affected.  
  
  
POPULAR SCIENCE SUMMARIES 
English 
The immune system can be seen as a collection of organs, cells, and barriers that block 
pathogens such as bacteria and viruses from entering the body and causing disease. However, 
threats can arise in the body itself, causing diseases such as cancer. In this thesis, I take a look 
at several cells of the immune system and their behavior when proteins of the actin 
cytoskeleton are affected. The cytoskeleton, much like our own skeleton, helps the cell 
maintain its form, move, and perform other important cellular functions. It is very important 
in the elicitation of proper immune responses against, for example, cancer. 
In papers I, II and IV we look at a protein called WASp and how it can affect the body’s 
immune response against cancer. In paper I, the disease we use as a model to study immune 
cells is called the Wiskott – Aldrich Syndrome. It is a so-called immunodeficiency and it is 
caused by mutations that lead to the Wiskott – Aldrich Syndome protein (WASp in short) 
being produced less or not at all. One of the symptoms of WAS is an increased risk of 
developing cancer. WASp is a very important protein for the cytoskeleton of the cell. Perhaps 
most importantly for the cells we study here, WASp controls the release of small vesicles in 
specialized cells that can kill infected or cancerous cells. These cells are called Natural Killer 
(NK) cells. In a person with a normal immune system, NK cells are one of the first cell types 
that will start responding to a threat. In WAS patients, however, and as we show here in mice 
that lack WASp, their NK cells are not capable of responding to stimulation. But when the 
tumor cells that we inject in the mice produce a molecule called IL-2, the NK cells from the 
WASp deficient mice can respond normally to tumors. This molecule is very important for 
NK cell function and it is now in clinical trials for preventing WAS patients from getting 
cancer. In paper II we take a look at another genetic immunodeficiency called X-linked 
neutropenia (XLN). It is also caused by mutations in WASp but the protein is instead 
overactive rather than absent. This causes a whole other set of symptoms in patients but still 
presents a heightened risk of developing cancer. We again took a look at the NK cells from 
mice that were engineered to express the mutant form of WASp. In the case of mice with 
XLN, their NK cells were remarkably capable of responding to stimulation and killing cancer 
cells, even more than in a normal mouse. We also got some material from these very rare 
patients with XLN and saw the same in their NK cells. In conclusion, NK cells from XLN 
mice might be a little bit too good. NK cells that are overactive are known to turn on the 
body’s own cells causing autoimmune symptoms. In paper V, we look at the role of WASp 
in the nucleus, the brain of the cell. We saw that WASp mediates the decision of what an 
immune cell should become. WASp is important for a cell to properly turn into a T cell. T 
cells are also important in the fight against tumors. When WASp is either absent or 
overactive, we saw that transcription of specific proteins was altered. This could contribute to 
the pathogenesis of the WAS and XLN syndromes. We therefore identified a new role for 
WASp in the nucleus in the development and functionality of T cells.  
In papers III and IV, we look at how the development of certain cancers is influenced by a 
specific protein and at a drug that influences the way immune cells respond to inflammation. 
Paper III involves another actin cytoskeleton regulator protein, called MKL1. MKL1 has 
been shown to be mutated in several cancer types. Here we looked at a specific type of blood 
cancer, called Hodgkin’s lymphoma, and how MKL1 could be involved in its development. 
We got blood samples from triplets that had a deletion in their MKL1 gene and 2 of the 3 
brothers had developed Hodgkin’s lymphoma. Interestingly, this deletion of MKL1 caused 
the protein to be overexpressed in the triplets’ immune cells. We could show that this 
overexpression of MKL1 caused their cells to behave in a way very reminiscent of cancer cell 
behavior. They would grow much faster, form extensions of their cytoskeleton capable of 
mediating metastasis and had problems keeping their DNA intact. We therefore concluded 
that mutations in MKL1 could be an underlying cause for Hodgkin’s lymphoma. In paper IV 
we used a drug against an enzyme that is very important in the regulation of various immune 
responses. This drug inhibited the enzyme’s function in immune cells called dendritic cells 
and caused the formation of fewer protrusions, indicative of highly motile cells, like cancer 
cells. Therefore, this drug could be a good solution for treatment of immune diseases, such as 
cancer. 
 
Svenska 
Immunsystemet kan ses som en samling av organ, celler och barriärer som blockerar 
patogener som bakterier och virus från att komma in i kroppen och orsaka sjukdom. Men hot 
kan uppstå i själva kroppen, vilket orsakar sjukdomar som cancer. I denna avhandling tittar 
jag på flera celler i immunsystemet och deras beteende när proteiner av aktincytoskelet 
påverkas. Cytoskelettet, liknande vårt eget skelett, hjälper cellen att behålla sin form, röra sig 
och utföra andra viktiga cellulära funktioner. Det är mycket viktigt vid framkallandet av ett 
korrekt immunförsvar mot exempelvis cancer. 
I artiklar I, II och IV tittar vi på ett protein som heter WASp och hur det kan påverka 
kroppens immunförsvar mot cancer. I artikel I använder vi en sjukdom som heter Wiskott – 
Aldrich syndromet som modell för att studera immunceller. Det är en så kallad immunbrist-
sjukdom och orsakas av mutationer som leder till att Wiskott – Aldrich Syndome proteinet 
(WASp i korthet) produceras mindre eller inte alls. Ett av symtomen av WAS är en ökad risk 
att utveckla cancer. WASp är ett mycket viktigt protein för cytoskelettet i cellen. För de celler 
vi studerat är WASp viktigt för att det kontrollerar frisättningen av små vesiklar i 
specialiserade celler som kan döda infekterade celler eller cancerceller. Dessa celler heter 
Natural Killer (NK) celler. Hos en person med normalt immunsystem är NK cellerna en av de 
första celltyperna som börjar reagera på ett hot. I WAS patienter, och som vi visar här hos 
möss som saknar WASp, kan deras NK celler inte reagera på stimulering. Men när de 
tumörceller som vi injicerar i mössen producerar en molekyl som heter IL-2, kan NK cellerna 
från de mössen utan WASp svara normalt på tumörer. Denna molekyl är mycket viktig för 
NK cellers funktionalitet och finns nu i kliniska tester för att förhindra WAS patienter från att 
få cancer. I artikel II tittar vi på en annan genetisk immunbrist som heter X-linked 
  
neutropenia (XLN). Den orsakas också av mutationer i WASp men i detta fall är proteinet 
överaktivt i motsats till frånvarande. Detta orsakar en hel annan uppsättning symtom i 
patienten men XLN patienter har också högre risk att utveckla cancer. Här tog vi en titt på 
NK cellerna från möss som konstruerades för att uttrycka den mutanta formen av WASp. I 
möss med XLN är deras NK celler anmärkningsvärt kapabla att reagera på stimulering och att 
döda cancerceller, ännu mer än i en vanlig mus. Vi fick också material från dessa mycket 
sällsynta patienter med XLN och såg samma i deras NK celler. Sammanfattningsvis kan det 
vara så att NK celler från XLN möss är lite för bra. NK celler som är överaktiva kan attackera 
kroppens egna celler och orsaka autoimmuna symptom. I artikel V tittar vi på rollen av 
WASp i kärnan, cellens hjärna. Vi såg att WASp medierar beslutet om vad en immun cell ska 
bli. WASp är viktigt för att en cell ska omvandlas till en T cell. T celler är också viktiga i 
kampen mot tumörer. När WASp är antingen frånvarande eller överaktivt såg vi att 
transkriptionen av specifika proteiner förändras. Detta kan bidra till patogenasen av WAS och 
XLN syndromen. Vi identifierade därför en ny roll för WASp i kärnan i utvecklingen och 
funktionaliteten av T celler. 
I artiklar III och IV tittar vi på hur utvecklingen av vissa cancerformer påverkas av ett 
specifikt protein och på ett läkemedel som påverkar hur immunceller svarar mot 
inflammation. Artikel III innefattar ett annat protein som reglerar aktincytoskelettet, kallat 
MKL1. MKL1 har visats vara muterat i flera cancertyper. Här tittar vi på en specifik typ av 
blodcancer, kallad Hodgkins lymfom, och hur MKL1 kan vara inblandad i utvecklingen av 
det. Vi fick blodprover från trillingar som hade en deletion i deras MKL1 gen och 2 av de 3 
bröderna har utvecklat Hodgkins lymfom. Intressant är att denna deletion av MKL1 orsakade 
att proteinet överuttrycktes i trillingarnas immunceller. Vi kunde visa att överuttrycket av 
MKL1 orsakade deras celler att uppträda på ett sätt som påminner om beteendet av cancer 
celler. De kunde växa mycket snabbare, bilda förlängningar av deras cytoskelett som skulle 
kunna mediera metastaser och hade problem med att hålla sitt DNA intakt. Vi drog därför 
slutsatsen att mutationer i MKL1 kan vara en bakomliggande orsak till Hodgkins lymfom. I 
artikel IV använde vi ett läkemedel mot ett enzym som är mycket viktigt vid reglering av 
olika immunförsvar. Detta läkemedel inhiberade enzymets funktion i immunceller som kallas 
dendritiska celler och orsakade bildandet av färre utsprång, vilket indikerar rörliga celler, som 
cancerceller. Därför kan detta läkemedel vara en bra lösning för behandling av 
immunsjukdomar, såsom cancer. 
 
Ελληνικά  
Το ανοσοποιητικό σύστημα μπορεί να θεωρηθεί ως μια συλλογή οργάνων, κυττάρων και 
φραγμών που εμποδίζουν την είσοδο παθογόνων οργανισμών, όπως βακτήρια και ιούς, στο 
σώμα και την πρόκληση ασθενειών. Ωστόσο, απειλές μπορεί να προκύψουν στο ίδιο το 
σώμα, προκαλώντας ασθένειες όπως ο καρκίνος. Σε αυτή τη διατριβή, ρίχνω μια ματιά σε 
διάφορα κύτταρα του ανοσοποιητικού συστήματος και τη συμπεριφορά τους όταν 
επηρεάζονται πρωτεΐνες του κυτταροσκελετού ακτίνης. Ο κυτταροσκελετός, όπως και ο 
δικός μας σκελετός, βοηθάει το κύτταρο να διατηρεί τη μορφή του, να κινείται και να εκτελεί 
άλλες σημαντικές κυτταρικές λειτουργίες. Είναι πολύ σημαντικός για την πρόκληση σωστών 
ανοσοαποκρίσεων έναντι, για παράδειγμα, του καρκίνου.  
Στα άρθρα I, II και IV εξετάζουμε μια πρωτεΐνη που ονομάζεται WASp και πως μπορεί να 
επηρεάσει την ανοσολογική απόκριση του οργανισμού ενάντια στον καρκίνο. Στο άρθρο Ι, η 
ασθένεια που χρησιμοποιούμε ως μοντέλο για τη μελέτη κυττάρων του ανοσοποιητικού 
συστήματος ονομάζεται σύνδρομο Wiskott – Aldrich. Το σύνδρομο αυτό είναι μια 
αποκαλούμενη ανοσοανεπάρκεια και προκαλείται από μεταλλάξεις που οδηγούν στο να 
παράγεται λιγότερο ή καθόλου η πρωτεΐνη Wiskott – Aldrich Syndome (WASp εν 
συντομία). Ένα από τα συμπτώματα του WAS είναι ο αυξημένος κίνδυνος ανάπτυξης 
καρκίνου. Η πρωτεΐνη WASp είναι πολύ σημαντική για τον κυτταροσκελετό του κυττάρου. 
Για τα κύτταρα που μελετάμε εδώ, υψίστης σημασίας αποτελεί το γεγονός ότι η WASp 
ελέγχει την απελευθέρωση μικρών κυστιδίων από εξειδικευμένα κύτταρα που μπορούν να 
σκοτώσουν μολυσμένα ή καρκινικά κύτταρα. Αυτά τα κύτταρα ονομάζονται Natural Killer 
(NK) ή κύτταρα Φυσικοί Φονιάδες στα ελληνικά. Σε άτομα με φυσιολογικό ανοσοποιητικό 
σύστημα, τα κύτταρα NK είναι ένας από τους πρώτους τύπους κυττάρων που θα αρχίσουν να 
ανταποκρίνονται σε απειλή. Ωστόσο, σε ασθενείς με WAS, και όπως δείχνουμε εδώ σε 
ποντίκια που δεν έχουν WASp, τα NK κύτταρά τους δεν είναι ικανά να ανταποκριθούν σε 
σημάδια ενεργοποίησης. Αλλά όταν τα καρκινικά κύτταρα που εισάγουμε στα ποντίκια 
παράγουν ένα μόριο που ονομάζεται IL-2, τα ΝΚ κύτταρα στα ποντίκια με ανεπάρκεια στη 
WASp μπορούν να αποκριθούν κανονικά σε όγκους. Αυτό το μόριο είναι πολύ σημαντικό 
για τη λειτουργία των ΝΚ κυττάρων και τώρα βρίσκεται σε κλινικές δοκιμές για την 
πρόληψη του καρκίνου σε ασθενείς με WAS. Στο άρθρο ΙΙ εξετάσαμε μια άλλη γενετική 
ανοσοανεπάρκεια που ονομάζεται X-linked neutropenia (XLN), ή ουδετεροπενία που 
συνδέεται με το χρωμόσωμα Χ στα ελληνικά. Προκαλείται επίσης από μεταλλάξεις στη 
WASp αλλά εδώ η πρωτεΐνη είναι υπερδραστήρια σε αντίθεση με απούσα. Αυτό προκαλεί 
ένα σύνολο διαφορετικών συμπτωμάτων στον ασθενή αλλά οι ασθενείς με XLN έχουν 
επίσης υψηλότερο κίνδυνο ανάπτυξης καρκίνου. Εξετάσαμε και πάλι τα κύτταρα ΝΚ από 
ποντίκια που κατασκευάστηκαν για να εκφράσουν τη μεταλλαγμένη μορφή της WASp. Στην 
περίπτωση των ποντικιών με XLN, τα ΝΚ κύτταρα τους είναι αξιοσημείωτα ικανά να 
αποκρίνονται και να σκοτώνουν καρκινικά κύτταρα, ακόμη περισσότερο από ότι σε ένα 
κανονικό ποντίκι. Έχουμε επίσης υλικό από αυτούς τους πολύ σπάνιους ασθενείς με XLN 
και είδαμε το ίδιο και στα δικά τους ΝΚ κύτταρα. Εν κατακλείδι, τα ΝΚ κύτταρα από XLN 
ποντίκια μπορεί να είναι λίγο καλύτερα από ότι θα έπρεπε. ΝΚ  κύτταρα που είναι 
υπερδραστήρια είναι γνωστό ότι επιτίθενται στα κύτταρα του ίδιου του σώματος, 
προκαλώντας αυτοάνοσα συμπτώματα. Στο άρθρο V, εξετάσαμε το ρόλο της WASp στον 
πυρήνα, τον εγκέφαλο του κυττάρου. Είδαμε ότι η WASp μεσολαβεί στην απόφαση για το τι 
θα γίνει ένα ανοσοποιητικό κύτταρο. Η WASp είναι σημαντική για ένα κύτταρο να 
μετατραπεί σωστά σε ένα Τ λυμφοκύτταρο. Τα Τ κύτταρα είναι επίσης σημαντικά στην 
καταπολέμηση των όγκων. Είδαμε ότι όταν η WASp είτε απουσιάζει είτε είναι 
υπερδραστήρια, μεταβάλλεται η μεταγραφή συγκεκριμένων πρωτεϊνών. Αυτό θα μπορούσε 
να συμβάλει στην παθογένεση των συνδρόμων WAS και XLN. Επομένως, προσδιορίσαμε 
  
έναν νέο ρόλο για την WASp στον πυρήνα και την ανάπτυξη και λειτουργικότητα των Τ 
κυττάρων. 
Στα άρθρα III και IV, εξετάσαμε πώς η ανάπτυξη ορισμένων καρκίνων επηρεάζεται από μια 
συγκεκριμένη πρωτεΐνη και πως ένα φάρμακο επηρεάζει τον τρόπο με τον οποίο τα κύτταρα 
του ανοσοποιητικού συστήματος ανταποκρίνονται στη φλεγμονή. Το άρθρο III 
περιλαμβάνει μια άλλη ρυθμιστική πρωτεΐνη του κυτταροσκελετού ακτίνης, που ονομάζεται 
MKL1. Η MKL1 μεταλλάσσεται σε διάφορους τύπους καρκίνου. Εδώ εξετάσαμε έναν 
συγκεκριμένο τύπο καρκίνου του αίματος, που ονομάζεται λέμφωμα Hodgkin, και πώς η 
MKL1 θα μπορούσε να συμμετάσχει στην ανάπτυξή του. Πήραμε δείγματα αίματος από 
τρίδυμα που είχαν διαγραφή στο γονίδιο MKL1 και 2 από τα 3 αδέλφια έχουν αναπτύξει 
λέμφωμα Hodgkin. Αυτή η διαγραφή του γονιδίου MKL1 προκάλεσε την πρωτεΐνη να 
υπερεκφράζεται στα ανοσοκύτταρα των τριδύμων. Μπορούσαμε να δείξουμε ότι αυτή η 
υπερέκφραση της MKL1 προκάλεσε τα κύτταρα τους να συμπεριφέρονται με τρόπο που 
θυμίζει πολύ τη συμπεριφορά καρκινικών κυττάρων. Μπορούσαν να πολλαπλασιαστούν 
πολύ ταχύτερα, να προκαλέσουν επεκτάσεις του κυτταροσκελετού τους που θα μπορούσαν 
να συμβάλουν στην μετάσταση, και είχαν προβλήματα στο να διατηρήσουν το DNA τους 
άθικτο. Συνεπώς, καταλήξαμε στο συμπέρασμα ότι οι μεταλλάξεις στο MKL1 θα μπορούσαν 
να αποτελέσουν υποκείμενη αιτία για το λέμφωμα Hodgkin. Στο άρθρο IV 
χρησιμοποιήσαμε ένα φάρμακο εναντίον ενός ενζύμου που είναι πολύ σημαντικό στη 
ρύθμιση διαφόρων ανοσολογικών αποκρίσεων. Αυτό το φάρμακο αναστέλλει τη λειτουργία 
του ενζύμου σε κύτταρα του ανοσοποιητικού συστήματος που ονομάζονται δενδριτικά 
κύτταρα και προκάλεσε το σχηματισμό λιγότερων προεξοχών που είναι ενδεικτικές 
εξαιρετικά κινητικών κυττάρων, όπως τα καρκινικά κύτταρα. Ως εκ τούτου, αυτό το 
φάρμακο θα μπορούσε να είναι μια καλή λύση για τη θεραπεία ανοσολογικών ασθενειών, 
όπως ο καρκίνος. 
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1 INTRODUCTION 
1.1 PRELUDE 
The main components of this thesis are the actin cytoskeleton, tumorigenesis and, perhaps 
most importantly, lessons learned from primary immunodeficiencies. While writing about 
these concepts, I find myself unable to neglect mentioning the story of David Vetter. David 
was born in 1971 and is, most affectionately, known as “the boy in the bubble”. He suffered 
from a disease called Severe Combined Immune Deficiency (SCID), which caused a 
complete absence of B and T cells. Being at a major risk for life-threatening infections, David 
lived in protected environments to maintain relatively germ-free surroundings at the Texas 
Children’s Hospital. The only treatment option at the time of David’s birth was bone marrow 
transplantation. After an exhaustive search to find a matching donor, David finally underwent 
surgery in 1984. Sadly, four months after his transplantation, David passed away from 
lymphoma caused by the Epstein-Barr virus (EBV).  
In my view, science has come a remarkably long way since then. There are diagnostic tools 
readily available for use in newborns and treatment options, such as gene therapy, that were 
long considered science fiction. This thesis attempts to discuss all of these breakthroughs and, 
hopefully, contribute to the information needed to cure, not only immunodeficiencies, but 
also other life-threatening immune disorders.  
 
1.2 THE IMMUNE SYSTEM 
Some of the first documented references of the immune system and immunity came from 
Hippocrates: “Natural forces within us are the true healers of disease” c. 460-370 BC, and 
Thucydides: “Though many lay unburied, birds and beasts would not touch them, or died 
after tasting them… [But] those who had recovered from the disease had now no fear for 
themselves; for the same man was never attacked twice, never at least fatally.” History of the 
Peloponnesian War, 431–428 BC.  
The immune system is a defense system comprising of numerous biological structures, 
processes, cells, and molecules that protects organisms against disease. The fact that we are 
constantly exposed to microorganisms but only rarely develop disease can be attributed to a 
well-functioning immune system. The functions of the immune system are (mainly) exerted 
by immune cells. All immune cells derive from precursors in the bone marrow, called 
hematopoietic stem cells, through a process called hematopoiesisA. The immune system is 
considered as having two branches; the innate immune system and the adaptive immune 
system. They are interconnected by various mediators and cells but have several distinct 
characteristics.  
                                                 
A
 Hematopoiesis: From Greek αἷμα "blood" and ποιεῖν "make", formation of the cellular components of blood.  
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1.2.1 The innate immune system 
The innate immune system is evolutionarily older than the adaptive and is found in both 
vertebrates and invertebrates. Recognition of pathogens by the innate immune system relies 
on a set of germline encoded receptors on the surface of innate immune cells. The innate 
immune response occurs within minutes or hours of infection. The first line of defense is 
molecular; various antimicrobial peptides and enzymes as well as the complement system, a 
collection of plasma proteins, target the invading pathogens for lysis or phagocytosis by cells 
of the innate immune system. The second phase of the response involves receptors on the 
surface of cells such as macrophages that recognize the pathogen as potentially dangerous. 
These receptors are termed pattern recognition receptors (PRRs) and can recognize three 
danger signals: non-self, missing-self, and altered-self
1
. Two other textbook characteristics of 
the innate immune system are the lack of antigen specificity and of immunological memory. 
However, the nonexistence of memory in innate responses has begun to be disputed
2–4
. There 
have been reports on plants and invertebrates that lack adaptive immune systems being 
protected against secondary infections. Mammals have also been shown to have the ability to 
build cross-protection against secondary infections independently of T and B cells. Moreover, 
innate immune cells such as NK cells and monocytes can display adaptive characteristics. NK 
cells, for example, have been shown to respond better to secondary stimulation and a pool of 
long-lived, self-renewing “memory NK cells” has been detected in mice5–8.  
The cells that perform the effector functions of the innate immune system belong to both the 
myeloid and lymphoid lineages. Myeloid cells include mast cells, granulocytes (neutrophils, 
basophils, and eosinophils), and monocytes. The latter can further differentiate into macro-
phagesB and dendritic cells (DCs). The lymphoid compartment of the innate immune system 
includes Natural Killer (NK), Natural Killer T (NKT) cells, and γδ T cells. For the purposes 
of this thesis, NK cells and dendritic cells will be analyzed further. 
 
1.2.1.1 Natural Killer cells 
Natural Killer (NK) cellsC, as their name suggests, are potent killers of virally infected or 
transformed cells and do so without prior sensitization. Recently, it became clear they are part 
of a larger innate lymphoid cell (ILC) group
9–12
. Like NK cells, ILCs lack antigen-specific 
receptors and only have germline encoded ones. ILCs are predominantly found in tissues that 
are in close proximity to commensal bacteria and other microorganisms, like the gut, skin, 
blood, and lungs. They are potent producers of cytokines upon stimulation and are important 
for tissue homeostasis and development. Analogy can be made to the T cell lineage; NK cells 
are the cytotoxic cells and the ILCs are the helper cells of the innate immune system.  
                                                 
B
 Macrophage, from Greek μακρός “large” and φαγεῖν “eat”. Macrophages are known as the “big eaters” of 
the immune system. The discovery of phagocytes is credited to Élie Metchnikoff in 1882.  
C
 The name “Natural Killer” was originally proposed by Eva Klein. 
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NK cells were first discovered in the 1970s when researchers were in search of tumor neo-
antigens that could activate T cell responses
13,14
. They were initially considered to be 
background noise and in vitro artifacts in T cell cytotoxicity assays from studies performed 
both with mouse and human cells
15
. That turned out not to be the case and the new cell type 
was named “Natural Killer” cell, since it could mount a rapid, naturally-occurring, cytotoxic 
response against YAC-1 Moloney leukemia cells
13
. This cytotoxicity was shown to not be 
mediated by T cells, B cells, or macrophages nor did it involve antibody dependent cell 
mediated cytotoxicity (ADCC)
13,14
. Therefore, it seemed like this was indeed a new cytotoxic 
cell type. NK cells would later be found in mice starting at 3 weeks of age and their numbers 
were most abundant in the spleen but they were also present in lymph nodes and the bone 
marrow
16
. Very soon after the discovery of NK cells, researchers believed in their potency 
against tumor cells and in the control of viral infections. What was elusive though was the 
mechanism by which NK cells specifically recognize these cells and mount a cytotoxic 
response, while leaving normal cells intact. Clues came from observations made in mice that 
NK cell cytotoxicity is controlled by genes in the H-2 locus and that NK cells were the cells 
responsible for “hybrid resistance”17. Hybrid resistance is a phenomenon where F1 hybrid 
mice rejected allogeneic but also parental hematopoietic grafts. But it was first in the 1980s 
when the “missing-self hypothesis” was formed and the lack of MHC Class I on the surface 
of target cells was found to be an extremely potent activating signal for NK cells
18
. Today, 
we know that apart from their role in direct elimination of tumor cells
19–21
 and being vital in 
the control of multiple infections
22,23
, NK cells have additional functions including 
maintaining the homeostasis in the lymphoid compartment, protecting against auto-
immunity
24
, and in reproduction and pregnancy
25–27
.  
NK cells develop in the bone marrow from the common lymphoid progenitor (CLP) that can 
also give rise to B and T cells and some DC subsets. The CLP goes on to become the pre-NK 
precursor (pre-NKP) that has lost the ability to become cells of the other lymphoid 
lineages
28,29
. The pre-NKPs differentiate into NKPs that now start to express the interleukin 
(IL)-15 receptor complex
28,29
 and NKPs further differentiate into immature NK cells that start 
to express NK1.1 and NKG2D but are not yet functional
30,31
. Thereafter, immature NK cells 
egress from the bone marrow and start to express DX5 and Ly49 receptors
30–32
. NK cells in 
the periphery can further mature into subset characterized by differential expression of 
CD11b and CD27
33,34
. Several cytokines and transcription factors are important for NK cell 
development, survival and homeostasis. Transcription factors Id2, T-bet, and Eomes
28,35,36
 are 
vital for NK cell differentiation and cytokines, such as IL-2 and IL-15
37,38
, are important for 
their survival, differentiation, and proliferation. Interestingly, IL-15 has been shown to be 
trans-presented by DCs
39
. In order for NK cells to be able to distinguish self from non-self 
they first need to be educated on what constitutes self. Inhibitory receptors that recognize 
MHC Class I are not only important for inhibitory signaling in NK cell effector responses, 
but also for tuning NK cell responsiveness prior to the effector phase
40–46
.  As a result of the 
education process, only NK cells that express inhibitory receptors for self-MHC Class I, and 
therefore can be inhibited by normal cells, will gain the capacity of effector functions. These 
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same NK cells will be able to recognize MHC Class I downregulation on the surface of, for 
example, tumor cells and respond with cytotoxicity against them.  
Apart from the education process, NK cell effector functions are controlled by signals via two 
groups of germline encoded receptors, the activating and the inhibitory receptors, as well as 
many co-stimulatory and adhesion receptors. The signals from all engaged receptors have to 
be integrated and the functional outcome of that is the decision of NK cell responsiveness vs. 
non-responsiveness
47–49
.  
Activating receptors signal via immunoreceptor tyrosine-based activation motifs (ITAMs) 
that are either a part of the receptor itself or of associated adaptor proteins. After ligand 
binding, ITAMs become phosphorylated by Src kinases
50
 and downstream signaling is 
initiated. Activating receptors found on NK cells include: CD16 (FcγRIII) binds the Fc part 
of antibodies and induces ADCC
51
. NK1.1 is a C-type lectin encoded by the NK gene 
complex (NKC) and is only expressed on NK cells in mice of the C57Bl/6 strain
52
. NKp46 
belongs to a receptor group called natural cytotoxicity receptors (NCRs) and is the only 
member of the group found in mice. In humans, additional members are NKp30 and 
NKp44
47
. They recognize ligands on the surface of stressed cells
53
 and viral 
hemagglutinins
54
. NKG2D is a C-type lectin, found on NK cells and some subsets of T cells, 
that recognizes ligands upregulated on stressed cells
55
. Ligands for NKG2D are Rae1, Mult1, 
and H60 in mice and MICA/B, and ULBP1-6 in humans, all of which share similarities with 
MHC Class I molecules
55
. Tumor cells initially expressing NKG2D ligands try to shed them, 
but that has been shown to cause enhanced anti-tumor NK cell responses
56
. DNAM-1 
functions both as an activating receptor and an adhesion molecule by binding its ligands 
CD155 and CD112
57
. DNAM-1 ligands are also upregulated on stressed cells and DNAM-1 
has been linked to maturation and education of NK cells
58,59
. Most of the members of the 
Ly49 Receptor family are inhibitory but there are some Ly49Rs that mediate activating 
signaling. Ly49D recognizes H2-D
d
, as does inhibitory receptor Ly49A that has a higher 
affinity for it
60
. Ly49H can recognize the m157 of cytomegalovirus (CMV) in mice and is 
responsible for the genetic resistance of some mouse strains to the virus
61,62
.  
Inhibitory receptors signal through immunoreceptor tyrosine-based inhibition motifs 
(ITIMs), which when phosphorylated recruit phosphatases to inhibit signaling that promotes 
NK cell activation. Src homology region 2 (SH2) domain-containing phosphatase 1 (SHP-1), 
SHP-2, and SH2 domain-containing inositol-5 phosphatase 1 (SHIP-1) are some of the 
phosphatases that can be utilized for inhibitory signaling
63
. The phosphatase recruited 
depends on which receptor is engaged. Inhibitory receptors include receptors that recognize 
MHC Class I, the Ly49R family in mice and the KIR family in humans, but also receptors 
that have other ligands instead of MHC Class I. The murine Ly49Rs are members of the C-
type lectin-like family and are also encoded by the NKC. There are 8-18 different Ly49 
genes, depending on the mouse strain, and they have extensive allelic polymorphisms
64–66
. In 
the C57Bl/6 mouse strain, the Ly49 locus codes for 10 receptors, 8 of which are inhibitory: 
Ly49A, B, C, E, F, G2, I and J. They all recognize MHC Class I molecules but the 
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recognition requires a peptide to be bound in the MHC Class I cleft, in order for the correct 
conformational change to be obtained
67
. The KIRs found in humans make up a family of 15 
members. They are Ig-like molecules containing two (KIR2D) or three (KIR3D) Ig-like 
domains. Their ITIM enables the recruitment of SHP-1 and inhibition of activating signaling. 
Inhibitory KIRs recognize HLA-C1, C2 and Bw4. The KIR repertoire differs between 
individuals but also on NK cells within one individual
40
. The CD94/NKG2A heterodimer, 
also encoded by the NKC, is expressed in both mice and humans. It interacts with the non-
classical MHC Class I molecules Qa-I
b
 in mice and HLA-E in humans
68,69
.  There are also 
inhibitory NK cell receptors whose ligands are not MHC Class I molecules. SLAM family 
receptors are expressed on cells of the hematopoietic lineage and are usually self-ligands. 
One SLAM receptor that is not a self-ligand and is expressed on NK cells is 2B4, which binds 
to CD48
70
. 2B4 has four tyrosine-based switch motifs (ITSMs), which recruits adaptor 
proteins including SAP. SAP mediates NK cell cytotoxicity but in the absence of SAP, the 
ITSMs of 2B4 bind to phosphatases, which induces inhibitory signaling
71
. KLRG1 is an 
adhesion molecule that recognizes E-, N-, and R-cadherins on the surface of epithelial and 
endothelial cells, and some DCs
72–74
. Cadherins have also been found to be downregulated on 
tumor cells
72
. KLRG1 is not only expressed on NK cells but also on activated and memory T 
cells
75,76
. On NK cells KLRG1 has been associated with education
77
 and on CD8
+
 T cells 
with exhaustion
78
. However, KLRG1 is dispensable for both NK cell and CD8
+
 T cell 
development and function, as seen in KLRG1-deficient mice
79,80
. KLRG1 will be discussed 
further in the results section. 
NK cell are rapid responders to activating stimuli due to pre-formed lytic granules that 
mediate their cytotoxic responses
81
. These NK cell granules contain a number of proteins, 
including a pore-forming protein termed perforin
82–84
 and a family of serine proteases called 
granzymes
85,86
. Perforin causes osmotic damage due to its binding of phosphorylcholine 
groups, polymerization and subsequent pore formation in the lipid bilayer of the target cell
87
. 
Granzymes synergize with perforin to trigger apoptosis in the target cell. Granzyme B, for 
example, triggers apoptosis via critical target cell caspases
87
. Death can also be induced in the 
target cell by signaling via FasL and TRAIL
88
. NK cells also secrete cytokines, such as 
Interferon (IFN)γ and tumor necrosis factor (TNF)α, as well as chemokines and growth 
factors, rapidly upon activation
89
. These can in turn activate other cells of the immune system 
like those of the adaptive immunity
89
.   
For NK cells to exert their cytotoxic functions they need to form contacts with their target 
cells. Granules are released into the target cell via the contact area between the two cells, 
termed the immunological synapse (IS)
90–94
. The IS was originally defined in the late 
1990s
95,96
, as the crucial junction between a T cell and an APC, which enables T cell 
receptors to interact with MHC molecules. NK cells have been shown to form ISs with target 
cells in a regulated, stepwise manner
97–99
. Upon initial encounter with the target cell, NK cells 
undergo brief, exploratory interactions
100
. Signals through activating receptors strengthen this 
interaction and, among others, integrin LFA-1 becomes activated and mediates firm adhesion 
to the target cell
101
. This initializes the first steps of IS formation, including protein tyrosine 
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kinase activation, PIP(4,5)P2 generation, F-actin reorganization
102–104
, and arrest of 
migration
105
. Polarization of the microtubule organizing center (MTOC) and lytic granules to 
the IS are also required for NK cell cytotoxicity. However, prior to polarization, lytic 
granules rapidly move along microtubules and converge upon the MTOC, which precedes 
NK cell commitment to cytotoxicity
106,107
. The effector phase of the IS formation is 
characterized by a commitment to cytotoxicity. After the commitment to cytotoxicity has 
been made, a de novo F-actin polymerization and reorganization occurs, largely dependent on 
members of the Wiskott – Aldrich syndrome protein family108, which will be discussed later. 
The requirement for F-actin also entails permitting granules to be released, which occurs in a 
pervasive actin network at the IS
109,110
. This involves proteins such as cofilin, coronin 1A, 
Myosin IIA and others
111–115
. NK cell lytic granules have been found to use at least two 
distinct modes of fusion: Complete fusion where granule content is completely discharged 
and the contents diffuse rapidly at the plasma membrane, and incomplete fusion, whereby 
formation of a transient fusion pore at the plasma membrane is accompanied by release of 
some but retention of most of the granules
116
. The latter may promote efficient recycling of 
lytic granule membrane after the release of cytotoxic effector molecules
116
. The last stage of 
the IS is the termination stage. During this stage, NK cells appear relatively inactive and have 
to initiate a termination of their response. One possible mechanism is via perforin-induced 
exposure of phosphatidylserine that binds to NK cells and signals to terminate the 
response
117
. Additionally, receptor downregulation has been shown, for example for CD16 
and NKG2D
118,119
. The final stage of cytotoxicity is defined by detachment from the target 
cell, the signal for which arises from the dying target cell and is caspase dependent
120
. Failure 
at the detachment stage can cause severe pro-inflammatory cytokine secretion and is 
therefore also a tightly regulated step
120
. After successful elimination of a target cell, NK cells 
can go on to kill additional target cells in a process called “serial killing”121. 
 
1.2.1.2 Dendritic cells 
Dendritic cells (DCs)D were also discovered in the 1970s
122–126
 and Ralph Steinman was 
awarded the Nobel Prize in Physiology/Medicine for his achievement, albeit they were first 
described by Paul Langerhans in the late 19
th
 century. DCs constitute a heterogeneous group 
of cells that are highly specialized in antigen presenting
127,128
. They were initially thought to 
be part of the myeloid lineage but it is now evident that they can derive from lymphoid 
progenitors as well
129,130
. DCs exit the bone marrow as immature cells and constantly capture 
particles from their environment and scan for potential threats. They express a wide range of 
PRRs including Toll-like receptors (TLRs) and scavenger receptors. There are two major 
subsets of DCs in mice, conventional DCs (cDC) and plasmacytoid DCs (pDC). cDCs are 
further subdivided into CD8
+
 or CD8
-
, with the former being mainly involved in cross-
                                                 
D
 Dendritic cell: From Greek δένδρον "tree", due to their tree-like morphology. The dendrites of DCs are 
distinct from the dendrites of neurons. 
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presenting antigens to CD8
+
 T cells via MHC Class I, while the latter present antigen via 
MHC Class II
131
. The final maturation stage the DCs reach is dependent on cytokine 
combinations and the niche which they occupy
132
. Cytokines important for DC differentiation 
and maturation are Flt3L and GM-CSF. After DCs capture and start processing the antigen, 
they mature and upregulate co-stimulatory molecules, such as CD40, CD80, CD83, CD86, 
and chemokine receptors, such as CCR7, to induce migration to the lymph nodes
133,134
. 
There, and at other secondary lymphoid organs like the spleen, DCs encounter T and B cells 
in specific areas called germinal centers. There they present the antigenic peptides on MHC 
molecules and if recognized, the cells of the adaptive immunity will be activated.  
Apart from their role in antigen presentation to T cells, DCs can induce tolerance through 
induction of regulatory T cells (Tregs) or deletion of potentially autoreactive T cell clones
135
. 
They can also interact with other cells of the immune system, such as NK cells to promote 
anti-tumor effects
136,137
, secrete pro-inflammatory cytokines
138
, and prime B cell responses
139
.  
 
1.2.2 The adaptive immune system 
The adaptive immune system appears later in the evolutionary tree and is found only in 
vertebrates. This is also evident by its vast complexity. The adaptive immune response starts 
days after an infection has begun and has to be primed by the innate immune system. The key 
to a proper adaptive immune response is antigen specificity and clonal selection of T and B 
cells that will eliminate the pathogen. Contrary to the innate immune system that employs 
cells of both myeloid and lymphoid lineages, adaptive immunity is exclusively mediated by 
lymphocytes. These originate in the thymus (T cells) or in the bone marrow (B cells) and 
have receptors that undergo gene rearrangements to recognize a specific antigen.  
 
1.2.2.1 T cells 
Up until the mid-1950s, the thymus, where T cellsE develop, was considered to be a useless 
organ that had become redundant during evolution, since it was seen to atrophy during a 
person’s teen years140. However, work mainly steered by Jacques Miller concluded that the 
thymus is an important organ for the induction of cellular, but also humoral, immunity
141
. 
During T cell development, hematopoietic progenitors migrate from the bone marrow to the 
thymus where they to generate a large population of immature T cell precursors or 
thymocytes
142
. In the thymus, T cells undergo a series of differentiation steps, which are 
                                                 
E
 T cells get their name from the thymus. The word thymus has uncertain origin; one speculation is that it is 
derived from its resemblance to the leaf of the plant Thymus vulgaris (thyme, Greek: θυμάρι). Alternatively, it 
comes from the Greek word θύμος, which translates to anger, heart, soul, desire, or life and has to do with its 
position in the chest above the heart, where emotions are felt, and ancient Greeks thought it might be the 
location of the soul.  
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typically defined based on the surface expression of CD4 and CD8, and happen at distinct 
microenvironments of the thymus
143,144
. Thymocytes first start as CD4
–
CD8
–
 double negative 
(DN) cells, then become CD4
+
CD8
+
 double positive (DP), and lastly mature into single 
positive (SP) CD4
+
 or CD8
+
 T cells
145
. The DN stage can be further subdivided into four 
distinct stages (DN1-4), based on their expression of CD44 and CD25
146
. The T cell receptor 
(TCR) is comprised of two chains, the α and β chains, and is constructed during the first two 
differentiation stages (DN2-3 and DP) via V,D, and J gene recombination
147
.  
CD4
+
 T cells are generally referred to as helper T cells (Th) and CD8
+
 T cells as cytotoxic T 
cells (Tc or CTL). Other T cell subsets are the T regulatory cells (Treg) and T cells that are 
part of the innate immune system, namely NKT, γδ T, and (mucosal associated invariant T) 
MAIT cells
148,149
. To ensure that T cells will be able to respond to alloantigens but not self-
antigens, additional selection processes take place in the thymus, namely positive and 
negative selection. Positive selection takes place in the thymic cortex and ensures that DP T 
cells express a functional TCR capable of recognizing antigen peptide-MHC complexes on 
the surface of antigen-presenting cells (APCs)
150
. Self-antigens are expressed on MHC 
molecules by cortical thymic epithelial cells (cTECs). Only the thymocytes that interact with 
MHC Class I or MHC Class II appropriately (not too strongly or too weakly) will receive a 
survival signal. Thymocytes that do not fulfill this step die in a process called "death by 
neglect". This process ensures that the selected T cells have an affinity that fulfils useful 
functions. DP T cells that have interacted well with MHC class II molecules eventually 
become CD4
+
 cells, whereas those that interact well with MHC class I molecules become 
CD8
+ 
cells
151
. When positive selection is completed, long-term survival of these T cells and 
migration into the medullar compartment of the thymus is ensured, where they undergo 
negative selection. While in the medulla, thymocytes are again presented with a self-antigen 
presented on the MHC complex of medullary thymic epithelial cells (mTECs)
152
. mTECs 
present all self-antigens present in the body through an enzyme called autoimmune regulator 
(AIRE), which turns on transcription of tissue-specific antigens that would not otherwise be 
present in the thymus. Thymocytes that interact too strongly with the self-antigen receive a 
signal that leads to apoptosis. Alternatively, some of these cells are selected to become Tregs. 
The remaining cells exit the thymus as immature, naïve T cells. This process is an important 
component of central tolerance and serves to prevent the formation of self-reactive T cells 
capable of inducing autoimmune diseases. 
T cells become activated by interaction of their TCR with peptide-MHC complexes and their 
co-stimulatory receptors (CD28, ICOS etc.) with their ligands. TCR engagement is usually 
known as signal 1 and co-stimulation as signal 2. T cells need both signals to become 
activated, since TCR signaling alone leads to anergy. The TCR is a complex of several 
proteins; the TCRα and β chains as mentioned above, but also molecules called the CD3 
proteins. These consist of CD3γ, δ, ε and ζ chains that arrange into CD3εγ and CD3εδ 
heterodimers and a CD3ζζ homodimer. The ζ chains contain a total of 6 ITAMs that can be 
phosphorylated and induce activating signaling
153
. Cytokines are also important for the 
proper activation of T cells and are referred to as signal 3. CD4
+
 Th cells, for example, can 
  9 
differentiate into multiple functional subsets, dependent on the cytokine milieu. IL-12 and 
IFNγ are critical cytokines for initiating the downstream signaling cascade to develop Th1 
cells
154
, which secrete mainly IFNγ and IL-2 and are involved in the elimination of 
intracellular pathogens. IL-4 and IL-2 are critical for Th2 differentiation, which mount 
immune responses against extracellular parasites and produce mainly IL-4, IL-5, IL-9, IL-13, 
IL-10, IL-25
155
. Other Th subsets include Th17, follicular helper T cells (Tfh), induced 
regulatory T cells (iTreg), the regulatory type 1 cells (Tr1), and the potentially distinct Th9 
cells
155
.  
T cells also express an assortment of inhibitory receptors on their surface. These facilitate the 
adjustment of T cell responses to fit the inflammatory milieu in which they became activated. 
Inhibitory receptors can act to limit both co-stimulatory signaling and receptor ligation. For 
example, cytotoxic T lymphocyte antigen (CTLA)-4 is an inhibitory receptor that becomes 
upregulated on activated T cells. CTLA-4 yields intracellular phosphatase activity that 
dampens signaling downstream of the TCR and CD28 and it also acts as a competing 
receptor for CD80 and CD86, which it has a higher affinity for than CD28
156
. Other 
inhibitory receptors include programmed cell death-1 (PD-1) and lymphocyte activation gene 
3 (LAG3)
157
. Blockade of these inhibitory receptors is being successfully explored clinically 
and aims to augment immune responses against various types of cancer
158,159
. This will be 
discussed more in subsequent paragraphs. 
Ultimately, the goal of a T cell response is to develop life-long immunity through the 
generation of memory T cells. Historically, memory T cells were thought to belong either to 
the effector or to the central memory subtypes
160
. Central memory T cells express CD45RO, 
CCR7, L-selectin (CD62L), and have intermediate to high expression of CD44
160
. Effector 
memory T cells lack expression of CCR7 and CD62L, but have intermediate to high 
expression of CD44
160
. Effector memory T cells are mostly found in the periphery, while 
central memory T cells are found in the periphery and in lymph nodes
160
. Subsequently, 
numerous other populations of memory T cells have been discovered, such as tissue resident 
memory T cells that reside in tissues like the skin
161
. The single unifying characteristic of all 
memory T cell subtypes is that they are long-lived and can quickly expand upon repeated 
exposure to their cognate antigen. 
 
1.1.2.2 B cells 
The first functional indication of the existence of cells that we now know as B cellsF came in 
the 1890s
162
 when a publication highlighted the importance of circulating “antitoxins” in 
immunity against diphtheria and tetanus. These antitoxins were later shown to be 
                                                 
F
 B cells get their name, not from the bone marrow, but from the bursa of Fabricius, an organ similar to the 
thymus that is found in birds, where they were initially discovered and characterized.  
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antibodies
163
 and the cells that produced them had pre-formed antibody receptors on their 
surface
164
. In 1965, Max Cooper and Robert Good published a landmark study that identified 
B cells as the mediators of the humoralG immune response. Working with chickens, they 
showed that cells that develop in the bursa of Fabricius (B cells) are responsible for antibody 
production and are distinct from the ones that develop in the thymus (T cells)
165
. 
In mammals, B cells derive from hematopoietic progenitors in the bone marrow. There, they 
develop from pro- to pre-B cells and thereafter to immature B cells. During these stages, they 
undergo V, D, and J gene recombination of the Ig heavy chain by enzymes RAG-1 and RAG-
2, which will form the pre-B cell receptor (BCR)
166
. The same process happens to the V and J 
genes that form the Ig light chains κ or λ, which will associate with the pre-BCR to form the 
BCR
167
. B cells also undergo positive and negative selection while developing in the bone 
marrow. Positive selection occurs through antigen-independent signaling via both the pre-
BCR and the BCR
168,169
 and if these receptors do not bind to their ligand, B cells do not 
receive proper signals and cease to develop. Negative selection occurs through the binding of 
self-antigen with the BCR
170
. If it binds strongly to self-antigen, the B cell undergoes one of 
four fates: clonal deletion, receptor editing, anergy, or ignorance
170
. After the selection 
process, immature B cells migrate from the bone marrow to the spleen and pass through two 
transitional stages: Transitional (T)1 and T2
171
. Within the spleen, T1 B cells transition to T2 
B cells
172
. T2 B cells differentiate further into either follicular (FO) B cells or marginal zone 
(MZ) B cells, depending on signals received through their BCR and other receptors
173
. Once 
differentiated, they are now considered mature or naïve B cells
172
. 
Antigens can activate B cells either with the help of T cells (T cell-dependent antigens) or 
without (T cell-independent antigens). T cell-dependent antigens cannot induce a humoral 
response in mice lacking T cells and generally lead to high-affinity antibodies. In T cell-
dependent responses, the antigen is internalized through the BCR, degraded, and presented to 
T cells via MHC Class II molecules
174
. Following ligation of the TCR, T cells upregulate 
surface CD40L and secrete cytokines, such as IL-4
175
. CD40L binds to CD40 on B cells and 
acts as a co-stimulatory molecule for B cell activation. The cytokines also induce B cell 
proliferation, class switching, and affinity maturation by somatic hypermutation
175
. B cells 
then form a germinal center in a lymphoid follicle and then differentiate into long-lived 
plasma cells or memory B cells
176
. T cell-independent humoral responses can be induced in 
animals lacking T cells but the antibodies produced tend to have lower antigen affinity. Since 
B cells need additional signals to be activated, when they are not coming from the T cells, 
multiple receptors on the B cell have to be engaged. This can be mediated by PRRs like TLRs 
or by extensive cross-linking of the BCR. B cells from T cell-independent responses 
differentiate into short-lived plasma cells that produce antibodies mostly of the IgM class
177
.   
                                                 
G
 Humoral immunity: From Latin: Humor “moisture”, refers to the immunity found in bodily fluids not 
mediated by cells. Hippocratic medicine defined 4 humors (black and yellow bile, phlegm and blood), which 
could influence people’s temperament and health. This is also present in the Indian Ayurveda system of 
medicine. Robin Fåhræus later concluded that the 4 humors were based on the observation of blood clotting.  
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1.2.3 Harnessing the immune system to treat cancer  
Cancer immunotherapy is a field that employs the inherent ability of the immune system to 
fight cancer. The earliest report of immunotherapy for cancer treatment is from 2600 BC 
Egypt, where pharaoh Imhotep used a poultice, followed by an incision, to facilitate the 
development of an infection at the site and cause regression of the tumor
178
. More recently, in 
the 1890s, William Coley was the first to describe necrosis of the tumor induced by bacterial 
toxins. One of the proteins responsible for the induction of this process was later identified to 
be TNFα. Even more recently, in the late 1980s, cellular immunotherapy for cancer was 
introduced by Steven Rosenberg and colleagues. They reported tumor regression in patients 
with metastatic cancer who underwent different types of specific active immunotherapy
179
. 
Hematopoietic Stem Cell Transplantation (HSCT) 
HSCT was originally attempted in 1957
180
 and continues to be the only form of stem cell 
therapy that is widely available today for patients with hematological cancers. In HSCT 
patients undergo myeloablative conditioning and receive donor hematopoietic stem cells, 
which give rise to new immune cells that will, hopefully, fight off the cancer with better 
results than the host’s own immune system had. This effect is known as the graft-vs-leukemia 
(GvL) effect. However, HSCT can come with the side effect of graft-vs-host disease (GvHD), 
in which the donor’s immune cells start attacking the recipient’s normal cells181. Efforts to 
further increase the success of HSCT by reducing rates of relapse, preventing and treating 
GvHD, reducing infectious complications, and increasing the availability of HSCT are 
constantly ongoing
182
.  
Cellular therapies  
In the early days of HSCT, one method to refine the procedure and minimize GvHD was to 
put blood cells in culture with IL-2. This would generate the so called lymphokine activated 
killer (LAK) cells. When autologous LAK cells were transferred to patients with metastatic 
disease, in conjunction with IL-2 administration, they were able to efficiently kill tumor 
cells
183
. LAK cells are now known to consist mainly of NK cells
184
.  Today, syngeneic and 
allogeneic NK cells are used for adoptive therapy of mainly hematological 
malignancies
185,186
. The process has been so refined that donor–host pair can be predicted by 
the expression of their KIRs, which is independent of the HLA-matching status
187
. T cells 
have also used in adoptive cell therapy, with some promising results in the treatment of solid 
tumors
188,189
. 
Cytokines 
Cytokines are constantly used by immune cells as mediators of immune responses. The tumor 
microenvironment is generally an immunosuppressive milieu and the use of appropriate 
cytokines could potentially reverse it to a more proinflammatory state. IL-2 was one of the 
first cytokines used clinically to induce anti-tumor immunity and is approved for treatment of 
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malignant melanoma and renal cell carcinoma
190
. However, IL-2 is also stimulatory for 
regulatory T cells, which might counteract the beneficial effects of IL-2 in cancer treatment. 
Therefore, IL-15 that acts exclusively to activate NK cells has been effective in clinical use, 
also in combination with a potent IL-15 superagonist
191–194
. IFNα and other cytokines have 
also been explored. 
Monoclonal antibodies 
In 1987, CTLA-4 was identified by James Allison and colleagues
156
 and was shown to inhibit 
T cell responses against tumor cells. Blocking antibodies against CTLA-4 were later shown 
to lift this inhibition from T cells allowing them to reject tumors in vivo
195
. Also in the early 
1990s, Tasuku Honjo and colleagues discovered a molecule expressed in dying T cells, PD-
1
196
 and was shown to be another inhibitory receptor on T cells. Both CTLA-4 and PD-1 
antibodies are now approved for clinical use with great success in hematological tumors
159,197
. 
Before these two, however, the first antibody treatment against cancer was anti-CD20 
(Rituximab), which was approved by the FDA for treatment of follicular lymphoma in 1997. 
Rituximab targets CD20 on the surface of B cells and leads to death of the target cell. 
Therefore it is used in the treatment of B cell hematological malignancies
159,197
. Interestingly, 
the efficacy of many monoclonal antibodies have been shown to not only be dependent on T 
cell inhibition but also on the induction of NK cell-mediated ADCC due to engagement of the 
antibody Fc part with activating receptor CD16
198–200
. 
Cancer vaccination via DCs 
As discussed in previous paragraphs, dendritic cells have many roles in controlling immune 
responses and in bridging innate and adaptive immunity. Therefore, DCs have for long been 
considered as optimal vaccines against cancer
201–208
. DC therapy invokes creating anti-tumor 
responses by triggering them to present tumor antigens to lymphocytes and thereby priming 
them to kill the tumor cells. One method of inducing DCs to present tumor antigens is by 
vaccination with autologous tumor lysates or antigenic peptides
209
. DCs can also be activated 
in vivo by expressing GM-CSF on tumor cells. This can be achieved by either genetically 
engineering tumor cells to produce GM-CSF or by infecting tumor cells with an oncolytic 
virus that expresses GM-CSF
210
.  Another strategy is to remove DCs from the blood of a 
patient and activate them ex vivo. They can be activated in the presence of tumor antigens, 
which can be either a single tumor-specific peptide/protein or a tumor cell lysate, and are then 
infused back into the patient
209
. Sipuleucel-T is the only therapeutic DC vaccine against 
cancer currently in use and is approved for the treatment of prostate cancer
208,211
. The antigen 
used is prostatic acid phosphatase (PAP), which is present in 95% of prostate cancer cells, 
and it has shown significant increases in patient survival.  
Receptor engineering  
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) has had some success, in for 
example, the treatment of malignant melanoma
188,189
. The limitation for T cell therapies lie in 
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the ability to isolate and expand high-affinity T cells clones that are restricted to tumor-
associated antigens and in their limited in vivo expansion potential. However, by using gene 
transfer technologies, T cells can be genetically engineered to express a unique high-affinity 
TCR or a chimeric antigen receptor (CAR), both of which confer novel tumor antigen 
specificities
212
. Treatment with CAR-T cells has been successful in B cell malignancies, 
which display restricted expression of CD19
213
. Recently, CAR modifications for NK cells 
have also been explored
214,215
, in autologous NK cells but also in NK cell lines, like NK-
92
216,217
. CAR-NK cells currently under investigation are anti-CD19 for B cell malignancies 
and anti-EGFR for breast cancer and brain metastases
218
.  
 
1.2.4 Primary immunodeficiencies 
Primary immunodeficiency diseases (PIDs) are a heterogeneous group of rare, chronic, 
genetic disorders that affect the immune system. The term has been expanded multiple times 
to include a wide spectrum of diseases
219
. The current 9 classes include combined T and B 
cell deﬁciencies, predominantly antibody deﬁciencies, congenital defects of phagocytes, 
genetic disorders of immune regulation, defects in innate immunity, autoinflammatory 
disorders, complement deficiencies, other well-defined immune deficiencies, and lastly 
phenocopies of PIDs
219
. According to the Immune Deficiency Foundation (IDF)H, there are 
more than 300 classified PIDs.  
All the aforementioned forms of PIDs are characterized by increased susceptibility to 
recurrent and/or severe infections, with the susceptibility to specific pathogens being 
dependent on the nature of the specific immune defect
220
. PIDs can arise from mutations in a 
single gene, generally arise early in life, and can affect one or multiple components of the 
immune system. SCID for example, which was mentioned in the prelude, can be caused by 
mutations in numerous genes, including IL2RG, ADA, IL7R, JAK3, RAG1, RAG2, DCLRE1C 
(Artemis), TCRD, TCRE, TCRZ, and CD45. What is also of interest is that in many PIDs one 
of the symptoms is autoimmunity. This potentially signifies that the threshold of activation is 
altered in immune cells from PID patients, not only to a higher threshold, which results in 
immunodeficiency, but also to a lower one. This could cause the cells to react less potently to 
real threats and at the same time mount a vigorous response to self, due to a breach in 
tolerance
221
.  
Of particular interest to this thesis are two immunodeficiencies caused by mutations in the 
Wiskott – Aldrich syndrome protein (WASp); the Wiskott – Aldrich syndrome and X-linked 
neutropenia. WASp is an important protein in the recruitment and remodeling of the actin 
cytoskeleton in response to receptor stimulation. These concepts will be further discussed in 
the second section. 
                                                 
H
 https://primaryimmune.org/ 
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1.3 THE ACTIN CYTOSKELETON 
ActinI is one of three filaments that comprise the cytoskeleton. The other two, intermediate 
filaments and microtubules, will not be discussed in the context of this thesis.  
It is undeniable that cell movement is an integral part of many biological processes, including 
effective immune surveillance
222,223
. The actin cytoskeleton allows for the formation of 
specialized subcellular structures, such as lamellipodia, filopodia, stress fibers, and focal 
adhesions
223
. Therefore, abnormal regulation or activity of cytoskeletal components is often a 
cause of several diseases, including cancer
224
, neurological disorders
225
, and PIDs. Actin is 
one of the most abundant proteins on Earth
226
 and is evolutionarily conserved in the 
eukaryotic cytoskeleton of organisms belonging to all taxonomic groups
227,228
. It has even 
been suggested that actin, tubulin, and histones have a common ancestral protein, based on 
their behavioral characteristics
229
. 
Actin exists in two forms; monomeric or globular (G-actin) and filamentous (F-actin). 
Regulating the homeostatic balance between these two actin forms ensures that cytoskeleton 
dynamics are carefully controlled and occur in response to extracellular stimuli
230–232
. The 
actin monomer is a 42 kDa protein that consists of four subdomains and is the basic unit for 
the double-stranded helical actin filament
233,234
. Actin is an ATPase
235
 and ATP hydrolysis 
plays an essential role in the transition to F-actin (Figure 1A). Actin monomers bind ATP 
and ADP tightly, provided that Ca
2+ 
or Mg
2+ 
is present. One of these divalent cations 
associates with the β- and γ-phosphates of ATP, stabilizing its interaction with actin233.  
 
Figure 1: Monomeric and filamentous actin. A. Actin has ATPase activity and the conversion of G-actin from 
ATP- to ADP-bound and vice versa is a dynamic process in the cell. B. Actin treadmilling. The conversion of the 
ADP- to ATP-bound actin ensures the formation of actin filaments at the barbed (+) end of the filament. This 
occurs in a speedy manner. The conversion of the ATP- to the ADP-bound actin leads to the monomers 
separating from the filament at the pointed (-) end. This process is much slower. 
The actin filament is produced with a process termed actin treadmilling, the kinetics of which 
are thermodynamically unfavorable
236
 (Figure 1B). However, once oligomers are formed, 
spontaneous actin assembly can occur, since the ATPase activity of actin is enhanced upon 
polymerization
237
. This is provided that the concentration of actin monomer is above a critical 
concentration (0.1μM)238. During this process, actin monomers join the barbed (+) end of the 
filament in the ATP-bound state and disassociate from the filament preferentially at the 
pointed (−) end primarily in the ADP state (Figure 1B). More specifically, the newly 
                                                 
I
 The isolation and characterization of actin is commonly attributed to F.B. Straub in 1942 but it was first 
observed experimentally in 1887 by W.D. Halliburton who gave it the name “myosin ferment”. 
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assembled part of the filament contains mostly ADP-Pi-bound actin with a cap of ATP-bound 
units at the tip, while older filaments have mainly ADP-bound actin. The ADP-Pi actin is 
structurally similar to ATP-actin
239
 and both are more structurally stable that ADP-F-actin
240
. 
The release of phosphate triggers conformational rearrangements in the filament that result in 
less stable and more flexible ADP-actin filaments
241
.  
While nucleotide-dependent conformational changes control the structure and stability of the 
actin filament, there are additional control points that ensure proper regulation of actin 
polymerization. Numerous proteins like GTPases and G-and F-actin binding proteins (ABPs) 
play key roles in the precise manner actin filaments are formed. These will be discussed in 
the coming paragraphs.    
 
1.3.1 Actin cytoskeleton structures 
The polymerized actin filaments can further organize into different types of architectures: 
branched and crosslinked networks, parallel bundles, and anti-parallel contractile structures 
(Figure 2). These structures can act as mechanical elements to drive cell shape changes and 
motility. The crosslinked, parallel and antiparallel structures are briefly described below 
while the branched actin network will be discussed in subsequent paragraphs. 
Crosslinked actin networks (Figure 2, i and iii) are involved in controlling the shape and 
mechanical integrity of the cell
242–246
. Proteins mediating actin filament crosslinking play no 
or little role during actin assembly. Instead, they connect existing polymerized actin filaments 
with each other, in order to generate a complex macroscopic structure
246–248
. Different 
crosslinking proteins provide different attributes to the actin filaments. For example, proteins 
that impose small crosslinking distances, such as fimbrin or fascin, pack the filaments close 
together into bundles
249,250
. Larger crosslinkers, such as filamin or α-actinin, are present in 
either bundles or networks, depending on their concentration
248,251–255
. Moreover, the rate at 
which actin networks are assembled can also influence the resulting structure. For instance, 
α-actinin preferentially generates long filaments instead of bundles when the rate of assembly 
is high
247
. These observations imply that there are multiple levels to control actin networks. 
Crosslinked actin networks, along with branched ones, are found in broad, sheet-like 
lamellipodial structures (Figure 2, iii). Lamellipodia are vital in providing the main driving 
force in two-dimensional cell motility
242
. 
Parallel actin networks (Figure 2, iv) are present in structures such as filopodia and 
microvilli
245,256,257
. As their name implies, parallel networks are made of actin filaments that 
are oriented with their barbed ends towards the same direction, usually facing the cell 
membrane, and result in finger-like structures. Fimbrin, fascin, and α-actinin are cross-linkers 
that make up these parallel networks and maintain the actin filaments in close proximity
258–
260
. Two mechanisms of how bundle formation is initiated have been proposed, one requires 
the Arp2/3 complex and the other involves proteins like formins or Ena/VASp
256,261–271
. 
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Antiparallel actin networks (Figure 2, ii) are important for cytokinesis and stress fibers that 
connect the cell cytoskeleton to the extracellular matrix via focal adhesion sites
272–278
. They 
contain the element of myosin-induced contraction. Crosslinking proteins, such as fimbrin 
and α-actinin, can also stabilize the actin bundles in the antiparallel configuration274. The 
interaction of myosin and antiparallel actin bundles is a two-step process that includes 
contraction and myosin-induced disassembly
264,279,280
. 
 
 
 
 
 
 
 
 
 
Figure 2: The actin networks of the i) crosslinked structures in cortical actin, ii) antiparallel contractile structures 
in stress fibers, iii) branched and crosslinked structures in lamellipodia and iv) parallel structures in filopodia. 
Figure modified from 
281
. 
As important as it is to construct actin filaments and networks, it is equally important to 
disassemble them in a regulated fashion. Firstly, the distinction between disassembly and 
depolymerization should be made; depolymerization occurs in the filament ends
282
 (Figure 
1B), whereas disassembly essentially disrupts the mechanical integrity of the actin 
networks
283,284
. Cofilin can use fragmentation or severing to break down actin structures
285
. It 
can also bind to actin monomers and inhibit nucleotide exchange
286
. Myosin can also mediate 
filament severing. Actin bundles have been shown to slide along the myosin-coated surface at 
low myosin density, whereas they are disassembled at high myosin density
287
. 
 
1.3.2 Actin cytoskeleton regulators 
The behavior of actin in vivo differs dramatically from that of purified actin in vitro. At the 
physiological actin concentration found in cells, over 99% would polymerize in mere seconds 
in a test tube. In contrast, approximately half of the total actin found in cells is not 
polymerized
226
. This difference can be attributed to actin binding proteins (ABPs) that 
regulate virtually all aspects of actin assembly. ABPs have different functions; some are 
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involved in severing and crosslinking, discussed above. Capping proteins, such as gelsolin 
and tensin, involved in capping of the barbed end to block the addition of new 
monomers
288,289
, and tropomodulin, which acts exclusively on the pointed-end
290
, all aim to 
decrease the overall length of the filament. The list of proteins that could be mentioned is 
endless, however, only three ABP groups will be discussed in more detail below, since they 
are of more relevance to this thesis.  
Actin monomer-binding proteins. Proteins that bind actin monomers play a crucial role in 
controlling the pool of unpolymerized actin, by sequestering actin monomers and thereby 
modulating their addition to and dissociation from actin filaments. One example of actin 
monomer-binding proteins is profilin. It is an abundant protein that binds to the barbed end of 
an actin monomer and sterically inhibits elongation at pointed ends, but not at barbed ends
291
. 
Another actin monomer-binding protein is MKL1, which acts as a sensor of G-actin in the 
cytoplasm and will be analyzed further down. 
Actin nucleation proteins. As mentioned above, nucleation of the actin filament is a 
thermodynamically unfavorable process and is additionally suppressed by proteins like 
profilin. Therefore, specific proteins are able to initiate actin polymerization in a regulated 
manner. One such protein is the Arp2/3 complex, which produces branched actin filaments. 
The actin-related proteins or Arps were created early during the evolution of eukaryotes, 
when the primordial actin gene was repeatedly duplicated and diversified into multiple 
protein families
292
. Arps share 17-52% sequence similarity with actin and are numbered 
Arp1–11, according to when they separated from actin. Arp2 and Arp3 are part of the Arp2/3 
complex, along with five other subunits: ARPC1-5. The Arp2/3 complex is inactive but when 
it binds to the side of an actin filament, Arp2 and Arp3 move closer together and form a base 
for the growth of a branch
293
. The free barbed end of the new filament elongates, whereas the 
Arp2/3 complex anchors the pointed end of the filament firmly to the side of the existing 
filament, creating characteristic 70° actin-filament branches
294–296
. These observations have 
given rise to the dendritic nucleation model for actin-network. An alternative mechanism for 
branch formation has also been proposed
297, called the ‘barbed-end nucleation’ model, where 
the Arp2/3 complex binds to the free barbed end of a filament and two filaments 
subsequently grow from the branch
298
. Regardless of how they are made, actin filament 
branches are quite rigid and stable for tens of seconds. They can be further stabilized by 
proteins like cortactin
299
 and cofilin
111
.  
Nucleation-promoting factors. A variety of proteins can activate the Arp2/3 complex to 
initiate actin polymerization and they all belong to the Wiskott – Aldrich syndrome protein 
family. This protein family currently consists of 16 members, including WASp and N-WASp, 
WAVE1-3, WASH, and newer members WHAMM and JMY
300,301
. All members share a 
conserved C-terminal domain (named VCA or WCA), required for Arp2/3 activation and F-
actin nucleation. They also contain several unique N-terminal domains
302
 that regulate their 
individual assembly into macromolecular complexes, subcellular localization and/or 
interaction regulator proteins. In this way, branched F-actin formation can be spatially and 
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temporally regulated throughout the cell and integrated downstream of various signaling 
pathways. There are also different regulatory mechanisms that govern the WASp family 
proteins. WASp and N-WASp are autoinhibited via intramolecular interactions and need 
activation by upstream proteins. WAVE proteins are instead constitutively active and their 
regulation downstream of Rac depends on the formation of protein complexes containing 
intermediary proteins. These differential modes of regulation are also reflected in the 
different biological activities of the proteins
303,304
. In that regard, WAVEs are generally 
required for the formation of lamellipodial protrusions and circular ruffles. Conversely, 
WASp and N-WASp are essential for the formation of specialized adhesive/invasive 
structures, termed podosomes or invadopodia, as well as being involved in the initial steps of 
clathrin-dependent internalization and in the movement of vesicles within a cell
302
. 
Additional weight will be given to nucleation-promoting factor WASp and actin monomer-
binding protein MKL1.   
 
1.3.3 WASp 
WASp contains several domains including the Ena-VASP homology domain 1 (EVH1), also 
referred to as WASp homology domain (WH1), a basic region (B), a GTPase-binding domain 
(GBD), a proline-rich domain (PPPP), and a catalytic domain (VCA) also referred to as 
WCA domain (where the W stands for WASp homology domain 2 (WH2)) (Figure 3). The 
VCA domain is formed by three independent, structurally defined regions: the Verprolin 
homology domain, which binds to G-actin, the Central region, and the Acidic region, which 
mediates a direct interaction with the Arp2/3 complex
305
. All these domains allow for strict 
regulation of activity both by autoinhibition and external signals.  
Structural studies demonstrate that under steady-state conditions WASp resides in an 
autoinhibited form, via binding of the GBD to the VCA domain (Figure 3A). This interaction 
prevents activation of the Arp2/3 complex
306
. WASp-interacting protein (WIP) associates 
with the EVH1 domain and stabilizes this autoinhibited configuration. WIP also protects 
WASp from degradation and facilitates the localization and maintenance of the cellular levels 
of WASp
307–310
. 
Rho family GTPases comprise a family of more than 20 members of small GTP-binding 
proteins that have key roles in rearrangement of the cytoskeleton, cell cycle progression, and 
vesicle transport
311
. The nucleotide-bound state of these GTPases is generally regulated by 
guanine nucleotide exchange factors (GEFs), which catalyze GDP to GTP exchange, and 
GTPase activating proteins (GAPs), which facilitate the hydrolysis of the bound GTP. 
Activation, by extracellular signals through various receptors, results in translocation to the 
plasma membrane thereby localizing their activity to discrete sites in the cell. The GTPase 
Cdc42 was the first protein shown to bind WASp and its interaction with the WASp GBD 
causes allosteric release of the C terminus, allowing binding of the Arp2/3 complex and actin 
nucleation (Figure 3B)
312–315
.  
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Figure 3: WASp in its inactive and active forms. A. The inactive form of WASp resides in an autoinhibited 
conformation. B. Upon receptor stimulation, WASp becomes activated by small GTPases and phosphorylation, 
which leads to its interaction with the Arp2/3 complex and the formation of branched actin filaments. 
Abbreviations: EVH1: Ena-VASP homology domain 1, B: Basic domain, GBD: GTPase-binding domain, PPPP: 
Polyproline domain, VCA: Verprolin homology/Central/Acidic domain.  
Other signaling or posttranslational events can also modulate WASp function, apart from the 
Rho GTPases
316,317
. WASp autoinhibition is also modulated by phosphorylation of the GBD 
at tyrosine (Y)291
318,319
. In the autoinhibited structure, Y291 is inaccessible to kinases. 
However, upon Cdc42 binding, the GBD is opened, allowing for phosphorylation of Y291 by 
SH2-containing tyrosine kinases, such as Src. Phosphorylated WASp is able to promote 
Arp2/3-dependent actin nucleation in vitro, independent of Cdc42 binding. This suggests that 
phosphorylation converts WASp into a constitutively active form that may function to 
potentiate the duration and magnitude of its cellular signaling in vivo
318
. Consistent with this 
possibility is the observation that overexpression of a phosphomimic mutant of WASp, 
Y291E, induces filopodium formation in macrophages
320
. Phosphorylation at Y291 also 
promotes WASp ubiquitination at lysine (K)76 and K81 within the WH1 domain
321
, 
providing a posttranslational mechanism to negatively regulate WASp in vivo. In addition to 
tyrosine phosphorylation, two serines (S), 483 and 484, which reside between the C and A 
domains, may also be subject to regulation via phosphorylation. Phosphorylation at these 
sites by casein kinase 2 induces a 7-fold increase in binding affinity between WASp and the 
Arp2/3 complex and significantly accelerates actin polymerization and nucleation in vitro
322
. 
 
1.3.3.1 WASp function in specific immune cells 
In the lymphoid lineages, WASp is necessary for the survival and homeostasis of terminally 
differentiated lymphocytes, but does not seem to play a big role in the development of early 
progenitors
323–325
.  
T cells: CD4
+
 T cell counts in WAS patients are usually within the normal to low range, but 
CD8
+ 
T cells are usually fewer
326,327
. Thymopoiesis is affected in WAS patients and WASp-
deficient mice
324,325
, with a reduced progression from double negative (CD4
-
CD8
-
) to double 
positive (CD4
+
CD8
+
) T cells found in mice. T cell receptor skewing has also been found in 
WAS patients
328
 and WASp-deficient mice
329
, with deviations from the diverse TCR 
repertoire taking place in older individuals. WASp-deficient T cells have been shown to be 
hyporesponsive after TCR-dependent activation
330–332
, the cytotoxic activity of CD8
+
 T cells 
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is impaired
333
, and WASp-deficient Tregs fail to suppress effector T cells
334–337
. The latter 
might be an underlying cause for the autoimmunity observed in WAS
338,339
. Defective 
activity of follicular T (Tfh) cells residing in the spleen, which proliferate poorly, exhibit 
defective differentiation, and undergo increased apoptosis could also be a cause for the 
altered antibody production seen in WAS
340
. Mutations that lead to constitutively active 
WASp cause a skewing in the CD4
+
/CD8
+
 T cell ratio in XLN patients, due to increased 
numbers of activated (HLA-DR
+
,CD57
+
,CD28
–
) CD8
+
 T cells
341
. TCR-dependent activation 
of T cells in XLN induces a normal response
341,342
, but T cells fail to adhere normally
342
. As 
briefly mentioned above, T cells exert their function by communicating with other immune 
cells via the immunological synapse (IS). Actin cytoskeleton remodeling and signal 
transduction has to occur for a proper IS to be formed. Upon ligation of the TCR, WASp is 
rapidly recruited to the IS to facilitate actin polarization. There it also mediates internalization 
of the TCR and sustains intracellular signaling, both of which do not occur  in WASp-
deficient T cells
330,343–350
. WASp-deficient T cells in mice also fail to polarize their cytokines 
towards the IS
351,352
 and have reduced migratory responses, both in vitro and in vivo
353,354
.  
B cells: Absolute counts of circulating B cells in WAS patients are normal or slightly reduced 
and class switched memory B cells are normal in numbers
355
. WASp-deficient B cells display 
hyperproliferation, heightened antibody responses, and enhanced differentiation into class 
switched plasmablasts
356
. There is also an enrichment of autoreactive naïve B cell clones
357
, 
which could contribute to the autoimmune phenotype of WAS patients. B cell receptor 
(BCR) signaling is impaired in WASp-deficient mice, with enhanced recruitment of negative 
regulators FcγRIIb and SHIP358. Memory B cells devoid of WASp exhibit impaired BCR and 
integrin signaling as well as chemotaxis in humans and mice
359
. WASp-deficient immature B 
cells, on the other hand, appear to have hightened BCR responsiveness, which promotes 
egress from the marginal zone of the spleen
358,360
. This could provide an explanation for the 
suboptimal T-independent antibody responses observed in WAS patients
356,359
. The number 
and function of B regulatory cells (Bregs) have recently also been shown to depend on 
WASp
361,362
, so their dysfunction could also contribute to the autoimmune phenotype of 
WAS. Activating mutations in WASp results in failure of B cells to adhere, proliferate, and 
secrete antibodies in response to BCR stimulation
363
. There is also increased apoptosis 
associated with increased genomic instability, which could be a cause of the higher risk of 
hematological malignancies seen in XLN patients
363
. 
NK cells: WASp-mediated regulation of NK cell killing is a big part of this thesis and will be 
discussed in conjunction with the results obtained during experimentation. NK cell 
populations are often expanded in WAS patients
108
. However, NK cells with WASp 
deficiency demonstrate impaired actin polymerization and perforin accumulation at the NK 
cell-tumor cell IS, resulting in significantly reduced NK cell cytotoxic activity
108
. XLN 
patients have reduced NK cell counts
364
, but not much is known about their function.  
NKT cells: NKT cells are almost absent in WAS, but their numbers appear normal in XLT
365
. 
Mouse studies suggest that NKT cell maturation
366
 but also function
365,366
 is impaired in 
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WASp deficiency. Moreover, murine NKT cells devoid of WASp exhibit poor responses to 
glycopeptide antigens and fail to home to the sites of infection, instead they are retained in 
peripheral lymphoid tissues
365,366
. The role of NKT cells in XLN pathogenesis is poorly 
explored.   
The role of WASp in the myeloid lineages seems to extend to the development of 
differentiated myelocytes. In XLN patients, bone marrow examination has revealed an 
intrinsic disturbance of myeloid differentiation, as maturation arrest was observed at the 
promyelocyte/myelocyte stage. Most defects due to WASp-deficiency in myeloid cells 
revolve around phagocytosis and podosome formation, both of which require vast actin 
remodeling. Myeloid cells from WAS patients exhibit impaired phagocytosis, since WASp 
has a role in forming the phagocytic cup
367–369
. In addition, monocytes, macrophages and 
dendritic cells from WASp-deficient humans and mice show almost completely abrogated 
assembly of podosomes
370,371
. 
Dendritic Cells (DCs): 
DCs are important in priming T cell responses via the DC-T cell IS
372
 and studies in humans 
and mice have shown that WASp-deficient DCs have a diminished T cell priming 
capacity
373–376
. DCs lacking WASp are also less capable of secreting pro-inflammatory 
cytokines
377,378
 and of forming an IS with NK cells leading to lower NK cell responses
379,380
. 
Additionally, WASp deficiency leads to decreased DC migration to the skin resulting in a 
local potentiation of inflammatory T cells
381
 and to increased antigen cross-presentation to 
CD8
+
 over CD4
+
 T cells
382
. Both of these mechanisms could contribute to the autoimmune 
skin pathology observed in WAS.   
Neutrophils and other granulocytes:  
Neutrophils are implicated in many immunodeficiencies, with neutropenia and recurrent 
bacterial infection being very common symptoms
383
. XLN leads to increased actin 
polymerization and increased cytoplasmic viscosity in neutrophil precursors, which affects 
mitosis and differentiation, and causes apoptosis in these cells ultimately leading to the 
clinical symptom of neutropenia
384
. WASp also plays important roles in neutrophil migration 
and adhesion, with both of those functions being diminished in murine models of WASp 
deficiency
385
. Mast cells that are devoid of WASp exhibit defects in granule exocytosis and 
cytokine production, with decreased capacity to respond upon FcεRI triggering386. 
 
1.3.3.2 WASp in cancer  
A major factor controlling the metastatic nature of cancer cells is their motility. Alterations in 
the signaling pathways controlling the regulation of motility can lead to tumor cell invasion 
and metastasis. As mentioned previously, the driving force for membrane protrusion and 
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motility is localized polymerization of actin filaments at the leading edge of the cell. 
Recently, several studies revealed that molecules that link migratory signals to the actin 
cytoskeleton, including Rho GTPases and the WASp family members, are upregulated in 
invasive and metastatic cancer cells
222,224,387,388
. 
PodosomesJ are conical, actin-rich, dynamic protrusions of the plasma membrane and have a 
polarized pattern of distribution in migrating cells, situated at the front border between the 
lamellipodium and lamellum
389,390
. They mediate cell contact with the extracellular matrix 
(ECM) and, importantly, induce ECM degradation at the contact sites. The formation of 
podosomes can be induced by oncogenic transformation of fibroblasts by v-src, suggesting 
the importance of these structures in oncogene-driven cell motility and invasion
391
. WASp is 
an essential component of podosomes in hematopoietic cells, such as macrophages and DCs. 
As already mentioned, DCs and macrophages derived from WAS patients, are unable to form 
podosomes
371,392
, which suggests that WASp has an important role in podosome formation. 
Structures of this type are referred to as podosomes when they are found in normal cells and 
as invadopodia when they are found in cancer cells. However, they are proposed to have the 
same physiological function, which is remodeling of ECM structures. N-WASp has also been 
shown to be necessary for the invasion of several cancer cell lines and localizes at the 
invasion front
393–395
.  
 
1.3.4 The Wiskott - Aldrich syndrome  
In 1937, German pediatrician Alfred Wiskott first described three brothers with a condition 
characterized by microthrombocytopeniaK, bloody diarrhea, eczema, episodes of fever, and 
recurrent ear infections. He concluded that these boys had a novel hereditary thrombopathy, 
since their sisters were not affected
396
. Almost 20 years later, American pediatrician Robert 
Aldrich reported a similar clinical phenotype in 16 out of 40 males, but not females, spanning 
over six generations of a single family he studied in 1954. This clearly pointed out the X-
linked mode of inheritance of the disease
397
. The condition was termed Wiskott - Aldrich 
syndrome (WAS) after the two physicians who first described it. The gene mutated in WAS 
(WAS) was later identified on the X chromosome (position Xp11.22–p11.23) by positional 
cloning
398
. The protein product of the WAS gene is called the Wiskott - Aldrich syndrome 
protein (WASp) and it is ubiquitously expressed in non-erythroid hematopoietic cells. The 
family that was initially described by Wiskott was confirmed almost 70 years later to have a 
deletion of two nucleotides at positions 73–74 of WAS399. This resulted in a frameshift and 
premature termination of the protein
399
. 
                                                 
J
 Podosomes: From Greek πόδι "foot" and σώμα “body, cell”. When researchers found these protrusions of 
the ventral membrane in v-src transformed fibroblasts, they considered these structures to be “cellular feet”. 
K
 Microthrombocyte: From Greek μικρός "small", θρόμβος "lump" and κύτταρο "cell", refers to the platelet. 
Loss of platelets is what causes the common symptom of excessive bleeding in WAS patients.  
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WAS is a rare primary immunodeficiency caused by loss-of-function mutations in the WAS 
gene and 5 mutational hotspots in the gene have been identified by molecular analyses
400
. The 
incidence of WAS is estimated at between 1in10
5
 and 1in10
6
 cases per live births
401,402
. WAS 
makes up approximately 3% of all primary immunodeficiency disorders in the European 
Society for Immunodeficiency registry
326
 and ranges from mild to severe, depending on how 
much of the protein expression is left
400
. Mutations that result in completely absent WASp 
cause classic WAS with a clinical phenotype of thrombocytopenia, eczema, recurrent 
infections, and an increased incidence of autoimmunity and malignancies
403,404
. Mutations in 
WASp that result in decreased protein expression cause X-linked thrombocytopenia (XLT), 
which is a milder disease characterized mainly by thrombocytopenia and occasionally milder 
eczema and immunodeficiency
405–407
.  
 
1.3.4.1 Tumorigenesis in WAS 
Malignancy is a complication frequently observed in PIDs
408,409
. The tumor incidence in 
WAS patients is estimated to be 13-22% with a median age of onset of 9.5 years
403,410
. These 
malignancies are aggressive and patients generally have a poor prognosis. Most common are 
lymphoreticular tumors including non-Hodgkin’s lymphoma (76% of the total tumors 
associated with WAS), both EBV and non-EBV driven
411
, but also Hodgkin’s lymphoma, 
Burkitt’s lymphoma, myelodysplasia, and acute lymphoblastic leukemia403,410,412–415. Non-
hematopoietic malignancies also occur with increased frequency
326
. CD8
+
 T cells devoid of 
WASp are hyporesponsive and incapable of polarizing their granules, especially against 
tumor B cell lines
333
. This could contribute to a lower tumor immunosurveillance in patients.  
 
1.3.5 X-linked Neutropenia 
X-linked Neutropenia (XLN) is caused by gain-of-function mutations in WAS. The first 
mutation identified was the L270P mutation, which replaces the conserved leucine 270 into a 
proline in the GBD of the protein
341
. Since then, more mutations have been described, 
including the I294T and S272P mutations
364,416
. All mutations result in the GBD of WASp 
decreasing its affinity to the VCA domain, affecting the autoinhibited state of the protein. 
This leads to WASp being constitutively active and to increased actin polymerization, 
independent of Cdc42. Symptoms of XLN include recurrent major bacterial infections, severe 
neutropenia and monocytopenia, decreased NK and B cell counts, but low to normal platelets 
and normal serum IgA levels
417
. Bone marrow analysis demonstrates a hematopoietic arrest 
at the promyelocyte stage. Clinically, these patients remain well and are responsive to G-CSF 
therapy
326
. 
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1.3.5.1 Tumorigenesis in XLN 
XLN patients have an increased risk of developing cytogenetic changes indicative of 
chromosomal instability, myelodysplasia, or acute myeloid leukemia
418–421
. The link between 
constitutively active WASp and chromosomal instability is also supported in a murine model 
of XLN
363
. B and T cells from mice with the I296T mutation in WASp showed increased 
genomic instability, including chromosomal breaks, doublet and fused chromosomes, and 
tetraploidy. This could potentially be an underlying, intrinsic cause for the increased 
development of hematological malignancies in these patients. 
 
1.3.6 Treatment of WASp-related immunodeficiencies 
What follows is a review of the treatment options currently available for immunodeficiencies 
with loss-of-function mutations in WASp. However, these are also applicable to other PIDs. 
Diagnosis: At the time of initial diagnosis, WASp protein expression by flow cytometry or 
Western blotting in peripheral blood cells is a rapid and effective screen for WAS
326,422,423
. 
Sanger sequencing of patient DNA is essential for confirming the diagnosis and should cover 
all exons and intron–exon boundaries, to identify possible splice site mutations326. Immune 
cell function and count tests can vary among patients and with time, but can be very 
important to assess an individual patient’s progression. The combination of genetic, protein 
expression, and lymphocyte count data can be used to predict the prognosis of a WAS patient 
at presentation and to design the most effective treatment regime
326
. Prophylaxis: Patients are 
currently given antibiotics and immunoglobulin replacement treatment regardless of the test 
results. However, treatments of more specific symptoms, such as viral infections and 
autoimmune symptoms like eczema, are managed on an individual basis. Hematopoietic Stem 
Cell Transplantation (HSCT): The first case of HSCT in the treatment of WAS was 
performed in 1978. It resulted in normal hematopoiesis and cure of hematological and 
immunological abnormalities
424
. Since then, practice has been refined by more conditional 
treatments prior to transplantation
326
, with the donor stem cell source and the age at transplant 
being the main determinants of transplant outcome in WAS
326,425
. However, advances in the 
accuracy of HLA matching, improved supportive care and earlier routing to HSCT, have 
yielded a marked improvement in the outcome of HSCT and phenotype correction, with 
overall survival rates greater than 90%
326
. Gene Therapy: Gene therapy employs modified 
viral vectors that contain the normal WAS gene and ex vivo transduction of autologous 
hematopoietic stem cells. This approach completely eliminates the risk of alloreactivity and 
since there is a proliferative advantage of cells that have the normal gene expressed
426
, there 
is a high success rate in reversal of the mutation. The first gene therapy study in WAS used a 
γ-retroviral vector427. This was unfortunately later shown in other diseases to cause retroviral 
insertion adjacent to oncogenes, resulting in leukemia in some of the patients
428
. Therefore, 
lentiviral vectors that cause far less insertional mutagenesis have since been 
implemented
429,430
. 
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1.3.7 MKL1  
The megakaryoblastic leukemia-1 (MKL1)L protein is a ubiquitously expressed 
transcriptional coactivator that transduces actin cytoskeleton rearrangements into gene 
expression via the transcription factor SRF. This ability of MKL1 is due to its sequestration 
in the cytoplasm where it binds directly to monomeric G- actin
431,432
, via its conserved RPEL 
motifs (Figure 4A). Actin monomers occupy the N-terminal domain of MKL1 and block 
importins from gaining access to its nuclear localization signal and thereby impairing its entry 
to the nucleus
433
. When cytoplasmic G-actin levels decline, due to actin polymerization 
downstream of Rho GTPases, MKL1 translocates into the nucleus where it regulates 
transcription of cytoskeletal genes via the SRF
431,432
 (Figure 4B). Recent evidence has also 
implicated nuclear actin in promoting MKL1 activation
434–437
. MKL1 binds to G-actin in the 
nucleus, and nuclear G-actin has been shown to facilitate nuclear export of MKL1 and to 
prevent MKL1 from activating SRF target genes
438
. 
MKL1 regulates many processes, including cardiovascular development
439
, remodeling of 
neuronal networks in the developing and adult brain
434
, megakaryocytic differentiation and 
migration
440
, and many others. Despite the diversity in the functions of MKL1, the majority 
of MKL1 knockout mice are viable and fertile
439,441
, possibly due to a functional redundancy 
between MKL1 and the other MRTF family members. Immunologically, MKL1-deficient 
mice have reduced platelet counts in peripheral blood and reduced ploidy in bone marrow 
megakaryocytes, suggesting a role for MKL1 in megakaryocyte differentiation and 
maturation
440
. They also show a similar phenotype to that of acute megakaryoblastic 
leukemia (AMKL) pathology associated with the chromosomal translocation t(1;22), in 
which the MKL1 and RNA-binding motif protein-15 (RBM15) genes are fused. 
 
 
 
 
 
Figure 4: MKL1 mode of action. A. When actin is abundant in the cytoplasm, MKL1 binds G-actin, which hides 
its nuclear localization sequence. B. Initiation of signaling pathways, via among others the Rho GTPase, leads to 
the polymerization of actin, loss of MKL1 binding to G-actin, and translocation of MKL1 to the nucleus. There 
it interacts with SRF, which initiates transcription of actin and actin-related genes.  
 
                                                 
L
 MKL1 is also known with many other aliases, including Myocardin-Related Transcription Factor A (MRFF-
A) and Megakaryocytic Acute Leukemia (MAL).  
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2 AIMS 
The overarching aim of the present thesis was to investigate the impact of actin 
cytoskeleton protein regulators on mechanisms of tumorigenesis and the immune system in 
general.  
The specific aims of the constituent papers were: 
Paper I: To characterize NK cell function in a mouse model of WAS and to investigate the 
potential of IL-2 treatment on WASp deficient NK cells in vivo. 
Paper II: To examine the NK and T cell function in mouse models and patients with 
activating mutations in WASp. 
Paper III: To investigate the role of actin regulator MKL1 in the development of 
lymphoma. 
Paper IV: To study the effects of a drug targeting a metabolic enzyme on the morphology 
and function of dendritic cells.  
Paper V: To elucidate the function of WASp in the nucleus of T cells. 
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3 MATERIALS AND METHODS 
All methodology used in this thesis is described in the individual papers. However, I would 
hereby like to mention a novel mouse model for molecular studies of WASp I aided in 
generating. The mouse model has yet to be featured in a paper, but I would like to bring 
forth its potential applications. We call it the Triple-Tag WASp mouse.  
Many of the antibodies used for WASp have been shown to be cross-reactive to N-WASp 
since they are designed for parts of the proteins that are identical; WASp and N-WASp 
share over 50% sequence homology. We therefore took the approach to engineer a mouse 
with WASp connected to various protein tags. Three individual protein tags were added 
into exon 1 of WASp, immediately after the start codon (Figure 5). The protein tags were 
three Flag tags, one Myc tag and one Avitag. Flag and Myc are well-established protein 
tags with highly functioning antibodies commercially available. They are commonly used 
for assays like immunoprecipitation (IP) and co-immunoprecipitation (co-IP). Avitag is a 
protein that contains a very specific amino acid sequence that can be biotinylated at an 
exact lysine (K) contained within it by a bacterial ligase called BirA
442
. This can be used in 
conjunction with fluorescently labelled streptavidin or anti-biotin to perform high 
resolution localization studies of WASp.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The genetics of the Triple-Tag WASp mouse. The three protein tags were added in exon 1 of 
WASp.  
The Triple-Tag WASp mouse can also be crossed with mice engineered to express BirA, to 
obtain specific in vivo biotinylation of the Avitag in vivo. Imaging experiments of WASp 
localization in response to stimuli can then be conducted. 
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4 RESULTS AND DISCUSSION 
4.1 WASP-DEFICIENT NK CELLS ARE CAPABLE OF RESPONDING TO 
TUMOR CELLS WHEN IL-2 IS PRESENT 
In previous mouse studies, data on WASp-deficiency and tumorigenesis has been 
somewhat contradictory. When WASp-deficient (WASp KO) mice were crossed with 
tumor-prone mice that lack cyclin dependent kinase inhibitor 2a (WASp KO x Cdkn2a KO 
mice), they had an accelerated onset of tumor growth when compared to Cdkn2a KO 
mice
380
. Moreover, WASp-deficient mice have increased tumor growth of subcutaneously 
injected B16 melanoma cells and show increased metastatic nodes
380
. This is attributed in 
part to decreased NK cell-DC cross-talk in WASp-deficient mice
380
. Using two other 
models, injection of MTLn3 or MDA-MB-231 breast carcinoma cells into mammary 
glands, primary tumor growth was shown to be indistinguishable between wildtype (WT) 
and WASp-deficient mice
443
. Interestingly, the metastatic spread was decreased in WASp-
deficient mice due to reduced capacity of tumor-associated macrophages to support cancer 
cell metastasis
443
. From these studies it is clear that the extent of how prone WASp-
deficient mice are to increased tumorigenesis may depend on the tumor context. 
In paper I, we utilized numerous lymphoma cells lines to assess tumor susceptibility in 
WASp-deficient mice, since most of the WAS patients develop hematological 
malignancies
403,410–415
. Using an in vivo imaging method we wanted to investigate the 
capacity of WASp-deficient mice to reject allogeneic tumor cells. We injected YAC-1 T 
cell lymphoma cells intravenously into Balb/c WT and WASp KO and monitored tumor 
cell rejection after a period of 5 hours (Paper I, Figure 1A). YAC-1 cells localize to the 
liver after intravenous injection and were located there in both WT and WASp KO mice 
during our in vivo imaging. However, YAC-1 tumor cell rejection was similar in both mice 
(Paper I, Figure 1B). This pointed out no defect in rejecting highly immunogenic 
allogeneic tumors in WASp-deficient mice. Next, we wanted to monitor tumor growth of 
the A20 B lymphoma cell line in WASp-deficient mice. We injected the A20 lymphoma 
cells subcutaneously into syngeneic Balb/c WASp-deficient and WT mice (Paper I, Figure 
6C). We followed the mice with in vivo imaging over a period of 6 days, to capture early 
tumor growth. During this period, we saw no difference in the tumor growth of A20 cells in 
WASp KO and WT mice. From this we concluded that the susceptibility to syngeneic 
tumors was not altered in WASp-deficiency either. The third tumor model we used to 
dissect the outcome of WASp-deficiency in tumorigenesis and to address the specific role 
of NK cells was the RMA/RMA-S competitive assay(Paper I, Figure 1C)
18,444
. Both are T 
cell lymphoma lines, but RMA has normal expression of MHC Class I and RMA-S is MHC 
Class I-deficientM. RMA and RMA-S cells were labelled with different concentration of 
                                                 
M
 Both RMA and RMA-S cells were generated by mutagenesis of the parental lymphoma cell line RBL-5, but 
the RMA-S cell line underwent additional repeated selection for low MHC Class I. They were instrumental in 
the formulation of the “missing-self” hypothesis.  
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CFSE and injected intravenously into syngeneic C57Bl/6 WT or WASp KO mice. 
Preferential rejection via missing-self of the RMA-S tumor was assessed after two days in 
the spleen of the mice (Paper I, Figure 1D). We found no difference in the rejection 
capacity of NK cells against RMA-S tumor cells. To further investigate the in vivo 
functionality of WASp-deficient NK cells we performed the same competitive assay with 
differentially CFSE labelled WT and β2m-deficient splenocytes (Paper I, Figure 1C). 
When assessing the rejection capacity of WASp KO mice after two days in the spleen, we 
saw a marked defect in β2m-/- cell clearance, compared to WT (Paper I, Figure 1E). This 
pointed to the fact that NK cells from WASp-deficient mice can respond to overwhelming 
activation signals from tumor cells, but cannot recognize lower activation signals coming, 
for example, from loss of MHC Class I on the surface of otherwise normal cells. NK cells 
from WASp-defient mice were also defective in vitro. They failed to degranulate and 
produce IFNγ in response to NK1.1 or NKp46 receptor stimulation (Paper I, Figure 5A). 
To test whether the in vitro and in vivo defects we observed were due to the phenotype of 
the WASp-deficient NK cells we assessed their development, maturation, and education 
status. The development of WASp-deficient NK cells in the bone marrow was normal since 
WASp-deficient mice had the same proportions of CLP, pre-NKP and NKP precursors as 
WT mice (Paper I, Figure 2B). Their maturation, based on CD11b and CD27, and their 
expression profile of inhibitory receptors were also indistinguishable from WT mice (Paper 
I, Figure 2C and D, respectively). 
We additionally observed that pre-incubation of the NK cells with IL-2 could rescue the 
functional defect of the WASp-deficient NK cells in vitro. The NK cells could respond with 
degranulation and IFNγ to the same extent as WT after IL-2 treatment (Paper I, Figure 5B). 
Moreover, with IL-2 pre-treatment WASp-deficient NK cells were capable of polarizing 
their actin towards the activating surface (Paper I, Figure 4E). We therefore wondered 
whether IL-2 could rescue the in vivo defect of WASp-deficient NK cells to reject MHC 
Class I-negative splenocytes as well. After injection of IL-2 treated NK cells to mice that 
had previously received MHC Class I-negative splenocytes, WASp-deficient mice were 
capable of rejecting them to the same extent as WT. We finally asked whether the ability of 
WASp-deficient mice to successfully respond against tumors was mediated by IL-2. 
Indeed, there have been reports of IL-2, as well as other cytokines, being produced by 
various lymphomas and act as growth factors for the tumor cells
445–448
. Moreover, we see a 
correlation between IL-2 and increased survival in both neuroblastoma and diffuse large B 
cell lymphoma patients when using the R2 database (Paper I, Figure 7E,F, respectively). 
When assessing the lymphoma cells lines we used in our experiments they were all high in 
intracellular IL-2 expression in vitro (Paper I, Figure 6A) and in vivo (Paper I, Figure 6B), 
and could secrete the IL-2 (Paper I, Figure Suppl.6B).  
To conclude, we show that IL-2 in vivo can modulate the responsiveness of WASp-
deficient NK cells in the tumor microenvironment. B16 cells, that do not normally express 
IL-2 (Paper I, Figure 6B), have been shown to have an accelerated tumor growth and 
increased number of lung metastases in the absence of WASp
380
. Additional evidence for 
the role of IL-2 in the tumor microenvironment comes from observations that expressing 
IL-2 in B16 melanoma cells decreased tumor growth and long-term tumor control
449
. This 
local expression of IL-2 in the melanoma could increase the frequency of NK cells and 
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effector T cells at the tumor site and delay tumor growth, despite a simultaneous increase in 
infiltrating Foxp3
+
 Tregs
449
. More specifically for WAS, IL-2 has been shown to induce 
WAVE2 activation, which compensates for the absence of WASp downstream of IL-2R 
signaling
450
. Importantly, IL-2 has been used in clinical trials for prevention of cancer 
development in WAS patients, with promising results in restoring immune cells
451
.  
 
4.2 NK CELLS WITH ACTIVATING MUTATIONS IN WASP DISPAY SIGNS OF 
HYPERACTIVATION 
Patients with XLN have mutations in WAS that lead to constitutive activation of WASp and 
a higher incidence of malignancies, as reviewed in paragraph 1.2.5.1
418–421
. Therefore, in 
paper II we wanted to test the rejection of tumors in our XLN mouse models, WASp
L272P
 
and WASp
I296T
. For this we made use of luciferase-expressing YAC-1 T cell lymphoma 
cells, injected subcutaneously, and in vivo imaging. The rejection of YAC-1 cells in normal 
mice is quite fast
452
 so we imaged the mice over a period of two days. We observed that the 
rejection capacity of WASp
L272P
 mice was indistinguishable from WT (Paper II, Figure 
1A,B). We additionally observed that WASp
L272P
 and WASp
I296T 
NK cells were still able to 
degranulate and produce IFNγ in vitro and in some cases did so to a higher extent than WT 
NK cells (Paper II, Figure 1D,E). We therefore wanted to test the in vivo functionality of 
NK cells in WASp
L272P
 and WASp
I296T 
mice. By using the in vivo rejection assay with 
MHC Class I-deficient splenocytes, we observed that after 48h, WASp
L272P 
mice were 
better than WT at rejecting them (Paper II, Figure 1C). There was also a marked difference 
in rejection capacity after 8h, with WASp
L272P
 showing increased rejection rates already 
then (Paper II, Figure 1C). This pointed out that NK cells from XLN mouse models were 
still capable of responding to stimuli and that they might have a lower threshold for 
activation. We excluded that the observed phenotype was due to a difference in WASp
L272P
 
and WASp
I296T 
NK cell maturation or education, by assessing markers CD11b and CD27 
and the inhibitory NK cell receptor repertoire (Paper II, Figure 2B and 2C,D, respectively).  
 
4.3 ACTIN POLARIZATION TOWARDS THE IMMUNE SYNAPSE IS IMPAIRED 
IN WASP-DEFICIENCY AND DYSREGULATED WHEN WASP IS 
CONSTITUTIVELY ACTIVE 
As discussed in the introduction, recruitment and remodeling of actin at the NK cell-target 
cell immune synapse is an important event in NK cell cytotoxicity
109,110
. NK cells from 
WAS patients cannot form functional synapses with tumor cells
108
. In accordance with 
those findings, we show in paper I that murine WASp-deficient NK cells fail to polarize 
their actin cytoskeleton towards tumor cells (Paper I, Figure 4C) or an activating surface 
(Paper I, Figure 4D). This is in conjunction with WASp-deficient NK cells being less able 
to localize their granules to the synapse as well (Paper I, Figure 4C). We therefore 
conclude that tumor cell killing is also impaired in WASp deficiency, when an NK cell-
sensitive tumor that does not secrete IL-2 is assessed, as shown previously
380
.  
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On the other hand, as we show in paper II, NK cells with activating mutations in WASp, 
WASp
L272P
 and WASp
I296T
, are still capable of polarizing their actin towards the synapse 
with tumor cells (Paper II, Figure 3B,C). We observed the same thing by using high 
resolution imaging to capture the F-actin structures towards an activating surface, coated 
with antibodies against NKp46 (Paper II, Figure 3D). However, when looking at 
WASp
L272P
 and WASp
I296T
 NK cell actin polarization towards surfaces without any 
activating antibodies, we observed actin polarization there are well, whereas WT NK cells 
did not polarize their F-actin towards those surfaces (Paper II, Figure 3D). This 
spontaneous actin polarization towards a surface that does not contain any activating 
ligands seen in WASp
L272P
 and WASp
I296T 
NK cells also supports the notion of these mice 
having a hyperactive phenotype in their NK cells.  
WASp and actin polarization in also important in the formation of T cell synapses and T 
cell-mediated cytotoxicity
333
. We therefore also assessed the ability of WASp
L272P
 and 
WASp
I296T 
CD4
+
 and CD8
+ 
T cells to form synapses with antibody-coated beads. Both T 
cell subtypes from the XLN mouse models were capable of polarizing their actin towards 
the beads, whereas WASp-deficient T cells were not (Paper II, Figure 5C-F).  
 
4.4 KLRG1 EXPRESSION IS INCREASED IN WASP-DEFICIENT AND 
DECREASED IN XLN NK CELLS 
To test whether the in vitro and in vivo WASp-deficient NK cell defects we observed in 
paper I were due to their phenotype, we assessed the expression of numerous activating 
and inhibitory receptors on naïve NK cells. The defects could potentially either be due to 
decreased activation signaling or increased inhibitory signaling. We observed that WASp-
deficient mice had higher KLRG1, CD69, DNAM-1, and LAG3 expression (Paper I, 
Figure 3A,B). KLRG1 and LAG3 are inhibitory receptors so increased expression of these 
two markers could cause the WASp-deficient NK cells to be hyporesponsive due to 
increased inhibitory signaling. DNAM-1 is an adhesion molecule that mediates activating 
signaling
57
 and CD69 is a co-stimulatory molecule that contributes to sustain NK cell 
activation
453
. Therefore, the impact of the expression of the last two markers on WASp-
deficient NK cells needs to be addressed with further experimentation. I would like to draw 
more attention to one of the inhibitory receptors, KLRG1.  
The inhibitory role of KLRG1 has mainly been demonstrated in humans
454–456
, where 
KLRG1 forms homodimers, something that proves essential for inhibitory function
79
. In 
experiments where KLRG1 is overexpressed in transgenic mice, NK cells could be 
inhibited by E-cadherin on K562 target cells but this was not observed at physiological 
KLRG1 levels. Hence, the inhibitory potential of KLRG1 in mice is rather weak and strong 
activation signals can override its inhibitory signal in vivo
79
. In their last CD11b/CD27 
maturation stage, NK cells start expressing KLRG1 and differentiating into CD27
-
CD11b
+
KLRG1
+
 NK cells
457,458
. Therefore KLRG1 is considered as a marker of NK cell 
maturation. KLRG1 has also been associated with NK cell proliferation and regulation of 
NK cell homeostasis, since KLRG1
+
 NK cells accumulate and have a slower in vivo 
turnover than KLRG1
-
 NK cells
458
. Interestingly, the importance of the CD27
low
KLRG1
+
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NK cell subset for effective antitumor immunity was highlighted by adoptive transfer of 
this subset into T-bet-deficient mice and suppressing lung metastasis formation in a murine 
model of colorectal carcinoma
459
. Importantly, immunity to metastasis formation could also 
be restored by IL-15, which induced the development of Eomes
+
KLRG1
+
 NK cells from 
existing populations
459
. Therefore, it is possible that is was the KLRG1
+
 NK cell 
population, which is increased in WASp-deficient mice, that mediated the anti-tumor 
response.  
We also characterized the NK cells from mice with activating mutations in WASp in paper 
II, to see if the phenotype of hyperactivity we observed could be due to increased activation 
signaling and decreased inhibitory signaling. The only differential expression we observed 
in WASp
L272P
 and WASp
I296T
 mice, compared to WT, was that of KLRG1. Both XLN 
mouse models had lower expression of KLRG1 (Paper II, Figure 2E). Therefore, it is 
plausible that the NK cell hyperresponsiveness seen in WASp
L272P
 and WASp
I296T
 mice is 
caused, at least in part, by NK cells with lower KLRG1-mediated inhibitory signaling.  
 
4.5 WAS PATIENT NK CELLS ARE HYPORESPONSIVE AND XLN PATIENT 
NK CELLS RESPOND NORMALLY TO STIMULATION 
We showed in paper I that splenic WASp-deficient NK cells were incapable of responding 
to stimulation in vitro and peripheral NK cells from WAS patients have been shown to 
respond less to stimulation
108
. We therefore also wanted to assess the ability of splenic NK 
cells from a WAS patient to respond to PMA and Ionomycin stimulation. There was a 
marked decrease in the degranulation and IFNγ production of the WAS patient’s NK cells, 
compared to healthy control (Paper I, Figure 7C). WAS patient NK cells had lower 
expression of CD56, leading to a large population of CD56
dim/negative
 NK cells (Paper I, 
Figure 7A). The WAS patient’s NK cells also had an increased expression of DNAM-1 and 
Granzyme B and lower expression of CD69 (Paper I, Figure 7B). 
Conversely, when assessing the XLN patients’ peripheral NK cells in paper II, we saw no 
major difference in the response of their NK cells to PMA and Ionomycin stimulation, 
compared to two healthy controls or their mother and sister (Paper II, Figure Suppl.2B). 
XLN patient NK cells had lower expression of KLRG1, much like their murine 
counterparts, and higher expression of Granzyme B (Paper II, Figure 4C,D, respectively). 
Interestingly, CD4
+
 and CD8
+
 T cells from the XLN patients had much higher expression 
of KLRG1 and higher Granzyme B content (Paper II, Figure 6B,C, respectively), but they 
could respond normally to PMA and Ionomycin stimulation. Their CD4/CD8 ratio was 
lower than in healthy controls, something that has been reported earlier
341
. Something new 
we observed in the XLN patients, however, was the appearance of a CD4
+
CD8
low
 T cell 
population, the significance of which should be further explored. Interestingly, this 
population has been shown to exhibit enhanced cytokine production, proliferation, and 
cytotoxic activity in viral infections, like HIV and CMV
460–462
. In conclusion, the 
phenotype and responsiveness of the NK cells from the XLN patients seems normal, 
however they exhibit a major loss of CD56
bright
 and CD56
dim
 NK cell populations in their 
peripheral blood (Paper II, Figure 4A), which could account for lower tumor surveillance. 
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Additionally, the responsiveness of their NK cells against K562 tumor cells is lower than 
the healthy controls’ (Paper II, Figure 4B).  
The discrepancy we saw between KLRG1 expression in the XLN patients and the murine 
models of XLN may have to do with the life span of humans and mice. The mice we used 
for our experiments are of young age, between 8 and 12 weeks. Comparatively, the patients 
we analyzed are in their late 20s. KLRG1 is associated with proliferation and KLRG1
+
 NK 
cells accumulate over time
458
. Since the age of analysis was so drastically different between 
the humans and mice, this could explain the difference in the KLRG1 phenotype. 
 
4.6 MKL1 IS IMPLICATED IN THE DEVELOPMENT OF HODGKIN’S 
LYMPHOMA  
The first thing I would like to bring up is that while MKL1 has been implicated in cancer, 
which will be discussed in detail underneath, complete MKL1 loss has been shown to lead to 
severe primary immunodeficiency
463
. A loss-of-function mutation in MKL1 found in a young 
girl caused reduced G- and F-actin content in lymphoid and myeloid cells, leading to 
widespread cytoskeletal dysfunction. MKL1-deficient neutrophils from the patient had a 
decreased phagocytic and migratory capacity and dendritic cells failed to spread and form 
podosomes.  
MKL1, as the name suggests, was first discovered as part of a fusion protein 
(MKL1/RBM15) in acute megakaryoblastic leukemia (AMKL)
464,465
. However, it is not 
clear whether the tumorigenic properties of the MKL1/RBM15 translocation results from 
reduced expression and altered specificity of RBM15 and/or MKL1, or whether the fusion 
protein possesses oncogenic properties. MKL1 has been implicated in several malignancies 
apart from AMKL, most notably in breast
466,467
 and liver cancer
467
. The function of MKL1 
in breast cancer in coupled to the function of the estrogen receptor (ER). The Rho/MKL1 
signaling pathway has been shown to be induced during the epithelial-mesenchymal 
transition. This results in an impaired ability of ER to efficiently transactivate estrogen-
regulated target genes. MKL1 could therefore be implicated in the suppression of the 
protective role exerted by ER against tumor progression and metastasis
466
. Deleted in Liver 
Cancer 1 (DLC1) is a tumor suppressor protein that is lost in cases of both breast and liver 
cancer. DLC1 loss leads to the activation of the Rho/MKL1 pathway and to permanent 
MKL1 nuclear localization, which leads to constitutive activation of its target genes. MKL1 
depletion in DLC1-defient cancer cells suppresses tumor cell migration, proliferation, and 
growth
467
. Recently, a deletion in MKL1 was found in two triplets who have developed 
Hodgkin’s lymphoma (termed HL1 and HL2)468. The deletion is situated in the first intron 
of MKL1 (Paper III, Figure 1B) so it is not predicted to affect the translated protein 
sequence per se but it might affect the transcription and/or posttranscriptional modifications 
of the RNA, and thereby affect the expression or function of the protein. The third triplet 
that carries the mutation remains lymphoma-free (HL0) (Paper III, Figure 1A).  
In paper III, we attempted to dissect the role of the MKL1 in the development of 
lymphoma. Hodgkin’s lymphoma has many characteristics of an inflammatory/infectious 
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disease with symptoms, such as fever and lymphadenopathy
469
, and has previously been 
associated with immunodeficiency
470
. Therefore, we subjected the triplets’ peripheral blood 
mononuclear cells (PBMCs) to the Flow-cytometric Assay for Specific Cell-mediated 
Immune-response in Activated whole blood (FASCIA), in order to assess their cells’ ability 
to respond to various stimuli (Paper III, Table Suppl.1). We found that their B cells 
responded well to most protein antigens, but displayed a decreased proliferation response to 
pokeweed mitogen.  
We obtained blood samples from the triplets with the MKL1 deletion, as well as from two 
age-and sex-matched controls. We analyzed both primary B cells and monocytes form the 
patients and generated lymphoblastoid cell lines (LCLs) by incubating PBMCs with EBV-
containing B95-8 cell supernatant
471
. Generating LCLs allowed us to perform additional in 
vitro experiments than allowed by primary cells. Interestingly, we were able to show that 
the MKL1 deletion led to an increased MKL1 expression in the triplets’ primary B cells and 
monocytes, compared to the healthy controls, when assessed by flow cytometry (Paper III, 
Figure 1D and Suppl.1C). In the LCLs, we were able to detect higher MKL1 mRNA and 
protein levels only in HL0, but not in HL1 and HL2 (Paper III, Figure 1C, E-H). To 
investigate the functional outcome of altered MKL1 expression in the triplets, we examined 
the transcription of several MKL1-target genes by RT-qPCR, including RAC1, TLN1, 
ITGB2, ACTB, and SRF. Transcripts of all MKL1-target genes assessed were increased in 
HL0 (Paper III, Figure 1I). Since MKL1 is involved in actin regulation, we examined the 
contents of F- and G-actin in both primary cells and LCLs. F-actin measurement by flow 
cytometry in primary B cells revealed higher F-actin content in HL2 and in primary 
monocytes all triplet cells had higher F-actin content (Paper III, Figure Suppl.1C). Only 
HL0 had higher G-actin content (Paper III, Figure 1K-M). To summarize this part of the 
study, we were able to pinpoint the phenotype of altered MKL1 expression in HL0, with 
increases in G- and F-actin content and in the transcription of MKL1-target genes.  
We next started to assess the LCLs obtained from the patients for signs of tumor 
transformation, including spreading, aggregation, proliferation, and genomic instability. 
Since actin is important for spreading responses in B cells, we examined the ability of the 
LCLs to spread on glass microscopy slides. HL0 and HL1 cells had an increased capacity to 
spread and to form long dendritic protrusions (Paper III, Figure 1N-O, Suppl.2A) and 
covered a larger adhesive area (Paper III, Figure 1P-Q). LCLs typically grow in clusters 
when in culture and their aggregation is dependent on adhesion molecules LFA-1 and 
ICAM-1. These are both induced by EBV transformation
472
. To quantify aggregation, we 
set up live cell imaging and measured clustering of the LCLs over a period of 2 hours. All 
LCLs apart from HL0 started forming aggregates right away. HL0 had a slower initiation of 
the aggregation process and ultimately formed smaller clusters than the rest of the LCLs 
(Paper III, Figure 2A-B). This aggregation defect in HL0 cells was probably due to lower 
expression of CD11a, a subunit of LFA-1, in HL0 LCLs (Paper III, Figure 2C-E). To 
address whether B cells from the triplets had altered proliferation compared to control B 
cells, primary cells were stimulated with anti-CD40 and IL-4 for 3 days and stained with 
the proliferation marker Ki-67. B cells from the triplets had higher Ki67 stained cells, 
indicative of their higher proliferative capacity (Paper III, Figure 2G). Conversely, in the 
LCLs the assessment of proliferation by means of [3H]-thymidine incorporation revealed 
  35 
that HL0 and HL2 had higher DNA synthesis rates (Paper III, Figure 2H). While 
performing Hoechst staining to address possible changes in the cell cycle of LCLs from the 
patients we observed, in accordance with the [3H]-thymidine experiments, that HL0 had 
more cells in the S and G2/M phase of the cell cycle (Paper III, Figure 2I). Interestingly, 
there were more HL0 and HL1 LCLs that had more than 4n DNA content, compared to the 
rest of the LCLs (Paper III, Figure 2J). This was excluded to be due to multinucleated, 
Reed-Sternberg-like cells (Paper III, Figure 2K). Lastly, LCLs from HL0 and HL1 had a 
higher proportion of cells with more than 46 chromosomes (Paper III, Figure 2L-M). 
In summary, we herein present the first association of an MKL1 mutation with Hodgkin’s 
lymphoma. The observed protrusions and increased spreading in HL0 LCLs could be 
associated with podosome/invadopodia formation. Decreased aggregation in the same 
LCLs, as well as increased proliferation and genomic instability could also imply a decline 
from the “normal” phenotype into a more mutational and metastatic state. The phenotype of 
cells obtained from HL1 and HL2 seems to fluctuate between the HL0 state and the healthy 
controls. On that note, it is of importance that the two triplets that previously developed 
lymphoma were treated in 1984 (HL1) and 2006 (HL2)
468
 and that the third triple could 
potentially represent a pre-lymphoma state. The fact that he has not developed lymphoma 
to this day could depend on multiple reasons, including environmental, epigenetic etc. 
Additionally, using the R2 databaseN we present transcriptional data of heightened MKL1 
expression in two types of lymphomas, compared to non-hematological cancers (Paper III, 
Figure Suppl.3).  
 
4.7 INHIBITION OF POSODOME FORMATION IN DCS WITH A 15-
LIPOXYGENASE-1 INHIBITOR  
15-lipoxygenase-1 (15-LOX-1) is a vital enzyme that mediates the metabolism of 
polyunsaturated fatty acids. Specifically, it catalyzes the introduction of molecular oxygen 
O2 as a peroxy residue into polyunsaturated fatty acids, especially arachidonic acid and 
linoleic acid. The expression of 15-LOX-1 is strictly regulated at the transcriptional, 
translational, and posttranslational levels
473
 and its expression is tissue- and cell-restricted. 
The enzyme is predominantly expressed in airway epithelial cells, eosinophils, alveolar 
macrophages, dendritic cells, and reticulocytes
469
. 15-LOX-1 has been found to be 
implicated in anti-inflammation, membrane remodeling, and cancer development and 
metastasis. 15-LOX-1-deficient mice exhibit a prolonged inflammatory response, which 
implicates the enzyme in resolution of inflammation
474,475
. The enzyme has roles in 
suppressing inflammation in diseases like eczema, rheumatoid arthritis, asthma, cystic 
fibrosis, atherosclerosis, adipose tissue inflammation, insulin resistance, and Alzheimer's 
disease
474,475
.  
15-LOX-1 is also implicated in cancer and has been mapped in close proximity to the 
tumor-suppressor gene p53
476
. Loss of the p53 gene, or gain-of-function activities resulting 
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from the expression of its mutant forms has been hypothesized to regulate the 15-LOX-1 
promoter activity in humans and in mice, albeit in directionally opposite manners
476
. In 
colorectal, breast, and kidney cancer, 15-LOX-1 is downregulated and its levels sharply 
decline as the cancer progresses
475,477,478
. Mouse studies suggest that 15-LOX-1 might be a 
tumor suppressor
479
. However, the data there is conflicting as well
480
. In monocytes, the 
expression of 15-LOX-1 is stimulated with cytokines IL-4 and IL-13, but not IFNγ481. All 
this collectively suggests that 15-LOX-1 is tightly regulated to mediate proper 
inflammatory responses. 
Hodgkin's lymphoma is considered a highly inflammatory type of cancer, with the Reed-
Sternberg cells, characteristic cells found in Hodgkin's lymphoma, constituting 
approximately 1-5% of the cell population in the tissue, while the rest of the tumor consists 
of immune cells
482,483
. There is also immense cross-talk between the immune cells and the 
tumor cells in Hodgkin’s lymphoma, which contributes to disease pathogenesis484. High 
expression of 15-LOX-1 has been detected in the Reed-Sternberg cells
485
. 15-LOX-1 has 
been suggested to operate through its products, like eoxins, and contribute to the 
development and/or morphology of Hodgkin's lymphoma
485
. For these reasons, inhibiting 
15-LOX-1 could be a viable option for Hodgkin’s disease therapy.  
As mentioned in paragraph 1.2.3.3, podosomes, or invadopodia as they are mostly referred 
to in cancer cells, are membrane protrusions with an ECM degradation activity formed by 
highly invasive tumor cells
222,389
. In paper IV, we use atopic and contact dermatitis as 
models for inflammation in humans, to dissect the role of DCs and 15-LOX-1. Human 
monocytes were shown to express 15-LOX-1 and produce 15-LOX-1 metabolites upon 
differentiation to DCs in culture (Paper IV, Figure Suppl.3). Importantly, we show that by 
using a novel specific inhibitor of the activity of 15-LOX-1, a substantial reduction in DC 
spreading and podosome formation was observed in vitro (Paper IV, Figure 3). The antigen 
uptake and migration capacity of the DCs were also reduced when 15-LOX-1 was inhibited 
(Paper IV, Figure 5A,B and C,D, respectively). This marked decline in DC migration could 
potentially in turn lead to less priming of T cell responses in the lymphoid organs the DCs 
would migrate to. Additionally, the impairment of the antigen uptake and processing 
capacity of the DCs could also lead to reduced T cell responses. However, when using the 
15-LOX-1 inhibitor or 15-LOX-1 shRNA in DCs we could only detect a minor effect on 
the T cell response (Paper IV, Figure 4A,B). Therefore, further refinement of the role 15-
LOX-1 in DCs is needed for it to be pharmacologically targeted. 
 
4.8 WASP RESIDES IN THE NUCLEUS AND IS INVOLVED IN THE 
REGULATION OF A T CELL-SPECIFIC TRANSCRIPTIONAL PROGRAM  
The concept that actin resides not only in the cytoplasm but also in its nucleus is now an 
accepted fact. However, it was received with a lot of skepticism for over 30 years when 
first observed in the late 1970s
486,487
. Early, and perhaps the most convincing, reports of 
actin in the nucleus came from studies using Xenopus laevis oocytes
488,489
. These identified 
actin as a component of the nucleus based on its ability to polymerize, be decorated by 
myosin motor domains, and bind DNase I, all hallmarks of actin. Actin regulators like N-
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WASp have also been found in the nucleus
490–494
. N-WASp is known to shuttle between the 
cytoplasm and the nucleus and is present in a large nuclear-protein complex within the 
nucleus
490
. This complex includes, among others, actin and RNA polymerase II and 
regulates gene transcription of target genes. The role of WASp in the nucleus is far less 
studied; WASp has only recently been found there and seems to directly mediate gene 
transcription
495–497
.  
T cell development, discussed in paragraph 1.1.2.1, heavily relies on the activity of the 
actin cytoskeleton. For example, the formation of immune synapses between thymocytes 
and antigen-presenting thymic stromal cells is essential for T cell differentiation and 
selection. Moreover, lineage commitment is controlled by specific transcription factors and 
those are in turn strictly regulated. T cell development is triggered by specific Notch 
signaling and the induction of transcription factors GATA3, TCF1, Bcl11b, and the E-
proteins HEB (TCF12) and E2A
498,499
.  
WASp is important for T cell development and function (paragraph 1.2.3.1) and clinical 
symptoms of WAS include both immunodeficiency and autoimmunity. This can be 
considered a bizarre combination, with immune cells both not reacting to external 
pathogens while vigorously responding to self. This can also be interpreted as WAS 
patients exhibiting defective Th1 yet maintain functional Th2 immunity, which could be a 
sign of WASp activity directly in Th1 immunity. WASp has previously been described as a 
transcriptional regulator of TBX21, a Th1 master regulator gene
495
. This is based on the 
observation that WASp exists in the nucleus and is present at the proximal promoter locus 
of TBX21, but not GATA3 (a Th2 regulator) or RORγt (a Th17 regulator), as is F-actin 
itself. Additionally, WASp could associate with enzymes responsible for histone 
methylation at the TBX21 promoter during Th1 differentiation. In human T cells that lack 
WASp, TBX21 promoter dynamics are repressed, which is followed by lower T-bet 
expression and impaired Th1 cell functionality. Importantly, the observed inhibition of Th1 
gene transcription and differentiation in the absence of WASp was ameliorated when 
WASp expression was restored in a patient-derived T cell line. Until now, the leading 
hypothesis for the molecular basis of WAS was the impairment of cytosolic actin 
polymerization. It is unclear how this causes a selective defect like the one observed in 
TBX21 gene expression and therefore suggests a role for nuclear WASp. Furthermore, 
murine T cells with overactive WASp and enhanced actin polymerization also have a defect 
in T-bet induction, which results in WAS-like immunodeficiency
500
.  Another link between 
WASp and gene transcription was drawn by the use of a WASp mutant defective in actin 
polymerization. This mutant WASp was seen to potentiate NFAT transcription following 
TCR engagement
496
. Moreover, in in vitro derived Th1 cells, WASp interacts with a subset 
of SWItch/Sucrose Non-Fermentable (SWI/SNF) complexes to drive transcription of 
TBX12-induced genes
497
.  
Based on these studies, WASp residing in the nucleus is undeniably playing a role in WAS 
pathogenesis and its role should be further dissected, as should its protein and DNA binding 
partners. To identify the genetic binding positions of WASp on a global genomic scale, we 
took the approach in paper V to perform chromatin immunoprecipitation followed by 
subsequent sequencing of the obtained gene fragments (ChIP-Seq) in mice.  
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Firstly, by using co-immunoprecipitation (co-IP), we observed that WASp localizes to the 
nucleus in thymocytes (Paper V, Figure 1A), which again highlights its potential role in T 
cell development, and in splenic CD4
+
 T cells (Paper V, Figure 1B), which speaks to the 
requirement of WASp throughout a T cell’s life. Interestingly, WASp was almost 
exclusively detected in the thymic nuclear extract, compared to the nuclear extract of spleen 
CD4
+
 T cells, which had equal amounts in the nucleus and cytoplasm. The significance of 
this remains to be uncovered. When performing the ChIP-Seq experiments, we identified 
257 WASp-interacting genes in thymocytes and 455 WASp-interacting genes in splenic 
CD4
+
 T cells (Paper V, Figure 1C). These datasets were obtained after exclusion of genes 
also found in antibody-free immunoprecipitations. When comparing thymic and splenic T 
cells, 15 common WASp-interacting genes were identified (Paper V, Figure 1C). WASp 
was found to cluster around transcriptional start sites (TSS) (Paper V, Figure 1D) and 
interacted with both intergenic and genic regions (Paper V, Figure 1E). Functionally, 
WASp was found to associate with RNA Polymerase II (RNA Pol II) genes (Paper V, 
Figure 2A), the functions of which can be categorized into 13 groups (Paper V, Figure 1F). 
These groups include for example transcription factors NFATC2 and TCF12. The WASp-
enriched sequences of TCF12, among others, were additionally found to have active 
epigenetic marks of transcription (H3K4m3, H3K9a, H3K27a) and of active enhancers 
(H3K4m1) (Paper V, Figure 2B). Therefore, we conclude that WASp mediates T cell-
specific transcription events.  
To assess if this active transcription we observed really was WASp-dependent, we 
performed a transcriptional activity assay in T cells from WASp-deficient mice. This assay 
entails the incorporation of fluorine-conjugated UTP (FUrd) analogues into nascent mRNA 
molecules
501
. WASp KO thymocytes showed less intense FUrd-rich foci compared to those 
found in WT thymocytes, suggesting that WASp is required for basal transcription (Paper 
V, Figure 4A-B). To understand exactly how WASp impacts specific gene transcription, we 
compared gene expression of proteins involved in cytoskeletal and transcriptional networks 
between WT and WASp KO thymocytes with real-time qPCR. We found that many of 
them were differentially expressed (Paper V, Figure 4C), suggesting WASp transcriptional 
involvement in specific genetic loci. Of the genes we investigated, many of them showed 
higher and others lower expression in the absence of WASp. This suggests that WASp is 
involved in both transcriptional activation and inhibition (Paper V, Figure 4D). We also 
assessed basal transcription levels in thymocytes expressing one of the constitutively active 
mutations in WASp, WASp
I296T
, and found similar intensity of FUrd-rich foci compared to 
WT thymocytes (Paper V, Figure 4A-B). This suggests that constitutively active WASp 
could still mediate transcription and does not alter the level of basal transcription. We also 
found that many genes were differentially expressed when WASp is constitutively active, 
with most of the genes tested showing higher expression in WASp
I296T 
T cells (Paper V, 
Figure 5B). 
TCF12 was one of the 15 WASp-enriched genes that was common between thymocytes and 
T cells from the spleen. We show that TCF12 expression is lower in WASp KO 
thymocytes, compared to WT thymocytes (Paper V, Figure 6A). Also, TCF12 had 
increased expression in WASp
I296T
 and WASp
L272P 
thymocytes, where WASp is 
constitutively active (Paper V, Figure 6A). We therefore conclude that the activation level 
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of WASp plays a big role in the subsequent expression level of TCF12 in the nucleus. To 
understand how the expression of these two proteins is connected, we checked WASp for 
any known binding sites of TCF12. Since we could not find any, by making use of gene 
ontology tools provided by MGI at NCBI Gene resource, we concluded that the interaction 
of WASp and TCF12 is indirect and perhaps mediated by a third party protein. 
Interestingly, we found that WASp-interacting genes were enriched for sequences identical 
to the binding sites of TCF1 (Paper V, Figure 6B). Similarly, we identified several TCF1 
binding sites in TCF12 sequences (Paper V, Figure 6C). To test the hypothesis that WASp 
and TCF1 interact, we performed co-IP experiments that showed WASp and TCF1 
interaction in nuclear extracts of thymocytes. Therefore, we conclude that nuclear WASp 
interacts with TCF1 to induce transcription of TCF1-target genes, which include TCF12 
and TCF1 itself.  
To summarize, paper V provides additional evidence on the existence of WASp in the 
nucleus and highlights its important role in the T cell-specific gene transcription machinery. 
TCF1 is one of the earliest transcription factors induced in T cell development
502
 and is 
required to induce the pre-TCR complex in developing thymocytes
503
. Pre-TCR signaling 
ensures that proper T cell selection and development occurs. The fact that TCF1 expression 
is dependent on nuclear WASp is highlighted by lower TCF12 expression in WASp-
deficient thymocytes. This could be part of the reason WAS patients and mice develop a 
skewed, autoimmune-prone T cell repertoire and that T cell responses via TCR stimulation 
as suboptimal. Moreover, we identify for the first time how nuclear WASp could be 
involved in the pathogenesis of XLN. Contrary to WASp KO thymocytes, WASp
I296T
 and 
WASp
L272P 
thymocytes had increased expression of TCF12.  
 
4.9 THE TRIPLE-TAG WASP MOUSE MODEL 
One concern when inserting a protein sequence into an already existing protein is whether 
that will be disruptive to the expression of that protein. The Triple-Tag WASp mouse was 
analyzed for its WASp expression and was found to retain WASp expression almost to the 
level of the wiltype (Figure 6A).  
We then tested whether WASp could be specifically detected with the use of anti-biotin and 
anti-Flag antibodies (Figure 6B). Streptavidin and anti-Myc staining yielded similar results 
(data not shown). We cultured dendritic cells for one week in the presence of GM-CSF to 
obtain large cells with distinct actin structures to see if we can localize WASp to them. All 
antibodies tested showed similar staining patterns limited to the Triple-Tag WASp cells and 
not present in DCs from WT mice. The staining, initially expected to localize to the actin 
structures, had a more perinuclear distribution.  
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Figure 6: A. WASp expression in the Triple-Tag WASp mouse (WASp-tag) analyzed by intracellular 
staining for flow cytometry and compared to a WASp-defient (WASp KO) and a wildtype (WT) mouse. B. 
Dendritic cells from Triple-tag WASp (WASp-tag) and WT mice and intracellular staining of F-actin 
(phalloidin) in red and anti-biotin (top), anti-Flag clone F1804 (middle), and anti-Flag clone F17425 (bottom) 
in green. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In my thesis, I have addressed the role of two actin cytoskeleton regulator proteins, WASp 
and MKL1, in the development of malignancy. Additionally, I have explored further roles 
of WASp in the nucleus and used an inhibitor to modulate an enzyme important for 
podosome formation. 
The specific conclusions from each paper can be summarized as follows:  
I. WASp deficiency is detrimental for NK cell-mediated anti-tumor responses unless IL-
2 is present.  
The role of IL-2 in the activation of NK cells has long been known. Interestingly, it seems 
to bypass signaling downstream of WASp and activates alternative pathways, fulfilling the 
need for NK cell activation in a proinflammatory, IL-2-containing environment. Therefore, 
our data is consistent with the notion that IL-2 is a vital component of the tumor 
microenvironment since overexpressing IL-2 in an otherwise IL-2 negative tumor could 
lead to the infiltration and activation of cytotoxic lymphocytes
449
. IL-2 has been shown to 
activate the WAVE2 pathway in humans, which is a WASp family member, and to initiate 
synapse formation in the absence of WASp
450
. The fact that WAS patients develop tumors 
due to their immunodeficiency is well-established. However, it is not known whether this is 
due to an immunosurveillance defect or whether their immune cells have intrinsic 
properties that make them tumorigenic since most of the tumors in WAS patients are 
hematological. The genetic instability in WASp-deficient cells has to our knowledge not 
been addressed. However, our data points more towards surveillance defects over intrinsic 
ones. The fact that patients can also develop non-hematological cancers, such as sarcomas, 
supports this notion. Additionally, the fact that we can rescue the WASp-deficiency defects, 
both in vitro and in vivo, points to a surveillance issue as well, which can be targeted by 
immunotherapy. Systemic administration of IL-2 was inefficient in restoring WASp-
deficient NK cell function in our hands (data not shown), but further refinement of the 
protocol is necessary to draw conclusions of IL-2 immunotherapy of WASp-deficiency in 
mice. Importantly, IL-2 is being tested in clinical trials for the prevention of cancer 
development in WAS patients and seems to be well-tolerated
451
.  
II. MKL1 is connected to lymphoma development. 
WASp overactivation compared to deficiency leads to a different set of symptoms in 
patients. However, the fact that both WASp absence and constitutive activation can have 
such detrimental effects speaks to the importance of actin cytoskeleton-related regulatory 
proteins. XLN patients also have a higher incidence of tumors, particularly hematological 
tumors of the myeloid compartment. This would argue for an intrinsic cause of tumor 
development. B and T cells have been shown to carry genomic instability and have high 
proliferation capabilities. Therefore, there may be cell cycle checkpoints that are inactivated 
in the constant activation status of WASp. This might be indicative of an additional role for 
WASp in the nucleus and investigating it could highlight potential mechanisms for 
tumorigenesis. NK cells and T cells when WASp is constitutively active seem to behave 
normally at an initial glance. However, in depth analysis of the synapse formation in NK 
cells from XLN mouse models revealed that they polarize their actin in the absence of 
activation signaling. Although seemingly trivial, this piece of data could indicate 
 42 
hyperactivity in these cells and a lower threshold for activation. Since receptor expression 
analysis revealed no big differences between wildtype and the XLN mouse models, one 
hypothesis is that intracellular signaling is heightened and WASp is indeed hyperactive. An 
investigation of signaling pathway activation along with a clarification of the activation 
status of WASp would, therefore, be of interest. In order to elucidate if this seemingly 
hyperactive phenotype leads to increased functionality of XLN NK cells, additional 
functional experiments need to be performed as well. Of particular interest would be to 
evaluate if NK cells from XLN mouse models actually kill tumor cells and, if so, if they 
perform better than wildtype cells. Therefore, the use of live cell imaging would be of great 
value. We have crossed all our mouse models (i.e. one WASp-deficient and two XLN) to 
mice expressing GFP-tagged actin. This would allow for high resolution, real-time imaging 
of synapse formation and tumor cell death.  
III. MKL1 is connected to lymphoma development. 
We have shown that in a study of triplets, of which 2 have developed Hodgkin’s 
lymphoma, MKL1 is overexpressed. This could be a potential link since MKL1 
translocations and mutations have been seen in cancers previously. We also show that many 
lymphomas have a higher expression of MKL1. These data are indicative of the role of 
MKL1 in cancer development. However, to provide a direct link, further experimentation is 
necessary. The accumulation of genomic aberrations while maintaining proliferation is one 
indication of tumor transformation. Therefore, it would be interesting to perform additional 
stainings for genomic instability on the cells from the triplets, for example with γ-H2AX. 
One way to establish a direct link between mutations in MKL1 and lymphoma development 
would be to inject the LCLs into NOD-Scid-gamma (NSG) mice and monitor tumor growth 
and metastasis. These mice are immunocompromised and can therefore be used for human 
cancer cell inoculation without any rejection of the cells. By doing this and locating the 
differences in tumor growth and spread between cells with normal and cells with higher 
MKL1 expression, we can provide an in vivo link between MKL1 and lymphoma 
development.  
IV. Small inhibitors of 15-LOX-1 can inhibit podosome formation. 
When inhibiting the enzyme 15-LOX-1, we perturb podosome formation in DCs. While 
this is an interesting observation, we could not detect significant differences in T cell 
priming. Therefore, further investigation of molecules that can potently do that should be 
performed. Alternatively, the inhibitor we describe should be used in combination with 
additional drugs to provide multiple hits against immune disorders.  
V. WASp in the nucleus mediates speficic T cell transcription. 
Altered transcription due to WASp could potentially explain many of the symptoms in 
WAS and XLN patients. The use of mutant WASp constructs that do not mediate actin 
polymerization but maintain its role in transcription would elucidate the regulatory 
mechanisms necessary both these functions. The Triple-Tagged WASp mouse would be of 
great aid in the localization of WASp. Mass spectrometry of WASp would reveal important 
binding partners and shed light on pathways important for WASp function. That could also 
provide useful information for compensatory mechanisms employed in WAS and XLN.  
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